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INTRODUCTION 
 
The portal venous system and portal hypertension (1-3) 
The veins of the portal venous system are unique since, unlike other veins, they do not drain 
directly into the systemic venous circulation or the heart. In stead, the portal venous system 
is the main vascular system supplying another organ, the liver. Normal total liver blood flow is 
approximately 1600 ml/minute; 1200 ml (75%) is delivered by the portal vein and 400 ml by 
the hepatic artery. The liver receives 25-30% of the cardiac output. Blood flow through the 
liver is higher than in any other organ and it is understandable that changes in hepatic 
resistance may have marked circulatory consequences.  
The portal system includes all veins that carry blood from the abdominal part of the intestinal 
tract, the gall bladder, pancreas and spleen. The portal vein is formed by the union of the 
splenic vein and the superior and inferior mesenteric veins anterior to the head of the 
pancreas and extends for a distance of 5 - 8 cm to the porta hepatis. There are two main 
branches while the further intrahepatic distribution is segmental, accompanying the hepatic 
arterial- and bile duct system. The inferior mesenteric vein usually enters the splenic vein 
before joining the superior mesenteric vein but may also enter the portal vein at the junction 
of the splenic and superior mesenteric vein.  
Portal hypertension is defined as a sustained increase in pressure in the portal venous 
system.  Portal pressure is the resultant of the volume of blood flowing through the portal 
venous system and the resistance to that flow. The normal portal pressure is usually 
expressed as the portal venous pressure gradient, i.e. the absolute pressure in the portal 
venous system minus the intraabdominal systemic venous pressure, and ranges from 3 to 6 
mm Hg (4). The absolute portal pressure can be elevated by ascites, increments in systemic 
venous pressure and other phenomena. Since any of these factors increase all 
intraabdominal venous pressures equally, it is essential to use an internal zero reference, 
e.g. the unwedged hepatic venous pressure or the inferior vena cava pressure, to correct for 
artificial effects on the portal venous pressure.  
Clinically significant portal hypertension, with formation of oesophageal varices, requires the 
gradient to increase above 10 mm Hg. Variceal bleeding is rarely observed when the portal 
pressure gradient is less than 12 mm Hg (5, 6). In patients with alcoholic cirrhosis, no 
relationship was found between the degree of portal hypertension and the risk of 
gastrointestinal bleeding or the size of oesophageal varices (7). Patients with varices 
receiving treatment with propranolol become protected against the risk of variceal bleeding 
when the gradient is lowered to 12 mm Hg or less (8). 
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Methods for the measurement of portal pressure (3, 9) 
Direct methods are transjugular transhepatic or percutaneous transhepatic catheterization of 
the portal vein, catheterization of a mesenteric vein during abdominal surgery and portal 
puncture after surgical recanalization of the umbilical vein. Indirect methods are the 
measurement of the free and wedged hepatic venous pressures at hepatic vein 
catheterization and splenic pulp puncture. The transjugular pressure measurement is 
routinely performed during transjugular intrahepatic porto-systemic shunt (TIPS) creation 
(10). Hepatic vein catheterization may be used for diagnostic purposes, for monitoring the 
effects of pharmacological therapy and as a prognostic tool (11). Pressure in oesophageal 
varices can be measured by direct puncture or by using endoscopic pressure-sensitive 
gauges. Several studies found that variceal pressure is significantly lower than is portal 
pressure owing to resistance offered by the portosystemic collateral vessels (12). The results 
obtained with the indirect endoscopic technique have been reported to be reproducible. This 
non-invasive method may be helpful for prognostic purposes (13) and for monitoring effects 
of pharmacological treatment of portal hypertension (14), and probably deserves introduction 
on a larger scale.   
 
Etiology of portal hypertension 
The etiology of portal hypertension can be subdivided in left-sided, pre-hepatic, intrahepatic 
and post-hepatic causes (table 1), according to the site of abnormality leading to portal 
hypertension.    
 
Left-sided (synonyms: segmental or sinistral) portal hypertension (15) (16) is an 
uncommon, loco-regional form of pre-hepatic portal hypertension involving the splenic 
venous territory, caused by an obstruction of the splenic vein. The most frequent causes are 
pancreatic cancer, pancreatic (pseudo)cysts, chronic pancreatitis and aneurysms of the 
splenic artery. This condition is characterized by the formation of collaterals in the gastric 
fundal region; oesophageal varices are usually absent. Awareness of this entity is of 
particular relevance since in patients with variceal bleeding splenectomy is curative.  
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Table 1. Classification of portal hypertension 
type    main causes  
 
left-sided   obstruction of splenic vein due to pancreatic disease 
pre-hepatic    portal vein thrombosis 
    compression/obstruction of portal vein due to cancer 
intrahepatic 
 pre-sinusoidal  schistosomiasis 
    (‘early’ cirrhotic stage of) PBC 
    congenital hepatic fibrosis 
    sarcoidosis 
    idiopathic portal hypertension 
    nodular regenerative hyperplasia 
 sinusoidal  liver cirrhosis   
 post-sinusoidal  veno-occlusive disease 
    hepatic vein thrombosis 
    metastatic tumor  
posthepatic   inferior vena cava thrombosis or web 
    constrictive pericarditis 
    congestive heart failure 
 
 
 
Prehepatic portal hypertension is caused by lesions obstructing blood flow or by an 
excessive inflow into the portal venous system (arterial-portal shunt) before it enters the liver. 
The prototype is portal vein thrombosis. Pressure is increased in the portal system proximal 
to the obstruction. Ascites is rare. It is important to realize that the hepatic venous pressure 
gradient is normal.  
 
Intrahepatic presinusoidal portal hypertension is characterized by abnormalities resulting 
in an increased resistance at the level of portal venules. The prototype is schistosomiasis. 
Ascites is rare and the hepatic venous pressure gradient is normal.   
 
Intrahepatic sinusoidal portal hypertension is the commonest type of portal hypertension 
encountered in the Western world. The prototype is alcoholic cirrhosis. Obstruction at the 
sinusoidal level is predominant and ascites is common. The hepatic venous pressure 
gradient is increased.  
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Intrahepatic postsinusoidal portal hypertension occurs in veno-occlusive disease as 
seen after bone-marrow transplantation and after ingestion of senechio alkaloids. Other 
causes include thrombosis of the main hepatic veins (Budd-Chiari syndrome), congenital 
hepatic venous webs and metastatic tumors. Ascites is a prominent feature. The hepatic 
venous pressure gradient is elevated.  
 
Posthepatic portal hypertension is caused by abnormalities outside the liver. Ascites is 
often intractable. Absolute portal pressure is increased but not the hepatic portal venous 
gradient.  
 
It should be noted that in many hepatic disorders there may be several areas of obstruction, 
and as the disease progresses new sites may become involved (2). Therefore, hepatic 
venous pressure measurements may yield results that differ from the typical findings listed 
here.   
 
Pathophysiology 
Increased portal resistance (2, 3) 
Normal portal hepatic blood flow is characterized by a low-resistance system: the pressure 
gradient between the portal venous system and the hepatic venous or systemic venous 
system, and thus hepatic resistance, is remarkably low. Portal venous blood flow into the 
portal system is actively regulated by changes in vascular tonus at the level of the splanchnic 
arterioles and by cardiac output. In the normal liver portal pressure remains low over wide 
ranges of portal flows.  
In most types of portal hypertension, the primary cause of an increase in portal venous 
pressure is an increased resistance to portal flow. Formerly, it was assumed that in liver 
diseases increases in portal resistance are attributable to (macro) structural abnormalities, 
including fibrotic scarring and nodule formation, leading to occlusion and compression of the 
normal vascular structures. However, in certain disorders, such as in alcohol-induced liver 
injury, other anatomical changes, including terminal hepatic vein fibrosis and collagen 
deposition in the perisinusoidal region or space of Disse, have been observed that are likely 
to contribute to portal hypertension. The transition of the permeable perisinusoidal space to 
an impermeable collagenous membrane has been described as capillarization. Other 
mechanisms involved may be hepatocyte enlargement, dropout of hepatocytes resulting in 
sinusoidal collapse, amyloid deposition and decreased sinusoidal fenestration. There are 
also data indicating that functional factors may lead to increased vascular tone. In liver 
disease hepatic lipocytes may acquire contractile characteristics that make them similar to 
myofibroblasts. They are postulated to play a role in the regulation of perfusion resistance.  
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These cells may also be the predominant source of collagen synthesis in alcoholic liver 
disease. More recently, studies have suggested an important role of vasoactive substances 
produced by endothelial cells such as endothelins, NO and prostacyclins.  Finally, the 
sympathetic nerve system may be involved in the modulation of intrahepatic resistance. 
Some of the factors potentially leading to increased resistance to blood flow should be 
regarded as irreversible. However, other factors, e.g. hepatocyte swelling, the production of 
endothelial vasoactive substances and sympathetic tone, may be reversible or amenable to 
pharmacological manipulation.  
 
When portal pressure increases, two physiological adaptive mechanisms, the development 
of portal-systemic collaterals and an increase in portal venous inflow, can be observed.  
 
Portal-systemic collateral circulation (1-3) 
Increased portal pressure is the main factor leading to the formation of portal-systemic 
collaterals. These vessels carry portal blood to the systemic veins and thereby decompress 
the portal system. Collaterals that are visible on endoscopic examination are usually 
described as varices but there is no fundamental difference between collaterals and varices, 
the distinction being a matter of semantics (17). The predilection site is the gastro-
esophageal junction where communications between the portal- and systemic venous 
circulation are present physiologically. Other sites where collaterals may form or develop are 
the anorectal region, the falciform ligament, the retroperitoneum and where veins of the 
portal and systemic venous communicate e.g. at the sites of intestinal-abdominal wall 
adhesions and enterostomies (18). Varices occurring outside the gastro-oesophageal region 
are known as ectopic varices. 
Although the collateral circulation begins as a consequence of portal hypertension, it evolves 
into an important mediator of the circulatory derangements in its own right. The vascular 
resistance of the collateral bed, although lower than that of the obstructed portal system, is 
nevertheless higher than normal portal resistance. The factors that modulate the 
development of the collateral system and that regulate flow through it are not yet completely 
understood. Animal studies have suggested that the endothelium derived relaxing factor NO 
is involved in modulating vascular resistance in the portal collateral system. Other humoral 
factors including 5-hydroxytryptamine as well as the adrenergic nervous system may also be 
involved.  
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Hyperdynamic circulation 
The second mechanism that has been demonstrated to be of importance in causing and 
maintaining portal hypertension is an increase in total portal inflow. This alteration is 
associated with a hyperdynamic circulatory state, particularly in the presence of advanced 
liver disease. The clinical manifestations are rapid pulse, warm extremities and low blood 
pressure. Hemodynamic studies show high cardiac index, low systemic vascular resistance 
and an expanded blood volume. Increased portal venous inflow is the result of arteriolar 
vasodilatation in splanchnic organs, which drain into the portal vein. The mechanism is likely 
to be multifactorial. Several studies have suggested that nitric oxide and other endothelial 
factors are involved. Also, other vasodilators of splanchnic origin, including glucagon, 
contribute to increase portal inflow. Increased production and reduced hepatic uptake from 
liver disease and shunting may increase circulating levels of these substances and decrease 
sensitivity to endogenous vasoconstrictors such as norepinephrine. Splanchnic 
vasodilatation is frequently associated with peripheral vasodilatation, which plays a major 
role in activation of neurohumoral systems, leading to sodium retention, expansion of plasma 
volume, and the development and accumulation of ascites.  
 
Complications of portal hypertension 
Portal hypertension can lead to a large number of physiological derangements and 
complications (table 2). The pathophysiology of these complications is variable and complex. 
Large portosystemic collaterals, or varices, can give rise to bleeding and this is one of the 
most frequent and serious complications of portal hypertension. Other complications seem 
related primarily to increased sinusoidal pressure (e.g. formation of ascites), diffuse portal 
vascular congestion and increased blood flow (e.g. portal hypertensive gastropathy), 
haemodynamic and hormonal alterations (e.g. hepatorenal syndrome; hepatopulmonary 
syndrome; GAVE) and increased portal-systemic shunting (e.g. hepatic encephalopathy; 
spontaneous bacterial peritonitis). However, in most conditions multiple pathophysiological 
pathways seem involved.   
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Table 2. Complications of portal hypertension 
Bleeding from varices 
- oesophageal varices 
 - gastric varices  
- ectopic varices 
Portal hypertensive gastropathy   
Portal hypertensive colopathy   
G(astric) A(antral) V(ascular) E(ctasia)  
Ascites       
Hepatic hydrothorax 
Hepatic encephalopathy 
Hepatorenal syndrome 
Hepatopulmonary syndrome 
Pulmonary hypertension 
Spontaneous bacteriaemia 
Spontaneous bacterial peritonitis 
 
 
Aim of the studies collected in this thesis 
Our work focussed on one of the most frequent and serious complications of portal 
hypertension i.e. variceal bleeding. In particular, studies were initiated aimed at developing a 
more effective therapeutic strategy for the primary and secondary prevention of variceal 
bleeding.  
 
Aspects of primary prevention of variceal bleeding are discussed in Chapters 2, 3 and 4.  
Primary prevention implies the need to identify patients at risk. Chapter 2 discusses the 
feasibility of a simple radiological method to detect oesphageal varices and addresses the 
reliability of this approach in comparison with the more usual endoscopic diagnostic method. 
 
The majority of patients with oesphageal varices will remain free of bleeding. On the other 
hand, in a proportion of patients variceal haemorrhage will be a fatal event. Therefore, 
identification of risk factors for variceal bleeding is of paramount importance, in particular with 
respect to selecting patients for prophylactic therapy. In chapter 3 we report a study 
assessing the reliability of the NIEC risk score system and report on attempts to further 
improve its prognostic reliability.  
 
Chapter 4 reports the results of a multicentre randomized controlled trial assessing 
sclerotherapy as prophylaxis for first variceal bleeding.   
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Variceal bleeding is a medical emergency associated with significant morbidity and mortality. 
In patients with active bleeding one of the medical priorities and challenges is to arrest 
bleeding. The results of a study on the use of thrombin as an endoscopic haemostatic agent 
are reported in chapter 5.  
 
A number of treatments have been proposed for the secondary prevention of variceal 
bleeding. Relative new therapeutic options are TIPS and endoscopic band ligation. In 
chapter 6 we report the results of a randomized controlled clinical trial comparing these 
treatment modalities, and discuss our results in the context of the cumulative results of 
comparable studies.  
 
TIPS is an innovative option for managing complications of portal hypertension. Chapter 7 
describes the experience obtained with TIPS in the Erasmus Medical Center in patients with 
variceal bleeding, refractory ascites and other complications of portal hypertension. Shunt 
obstruction developing over time is the recognized main technical weakness of TIPS. We 
analyzed risk factors for shunt obstruction and the long-term patency rate of TIPS in a cohort 
of patients followed according to a strict surveillance protocol; these results are also 
incorporated in this chapter. 
 
We have always had a main interest in particular sub-groups of patients with variceal 
bleeding. Bleeding from ectopic varices is rare and literature data other than case reports are 
equally rare. In chapter 8 we report our experience with 22 patients, observed over an 18-
year period. The results of a therapeutic strategy, consisting of an initial local therapy 
followed by a shunt procedure as second-line treatment when indicated, are presented and 
discussed.  
 
In our part of the world variceal bleeding in patients with portal vein thrombosis is infrequent 
and remarkably few studies have evaluated the efficacy of endoscopic therapy and long-term 
course in Western populations. In chapter 9 a series of consecutive patients with this 
condition is reported as well as the long-term results obtained with endoscopic sclerotherapy. 
 
Another relatively rare condition is portal biliopathy, an intriguing and unfamiliar complication 
of portal hypertension in patients with portal vein thrombosis. Chapter 10 summarizes our 
observations in a series of patients and discusses pathophysiological, diagnostic and 
therapeutic aspects.  
 
Chapter 11 summarizes and discusses the studies incorporated in this thesis.  
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Chapter 12 suggests guidelines, based on the results of recent international consensus 
meetings and own experience, for prophylaxis and treatment of oesophageal and ectopic 
variceal bleeding.   
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ABSTRACT 
 
Although barium swallow is a quick and easy method for diagnosing oesophageal varices, 
there is considerable variation between observers because objective quantitative radiological 
criteria have so far not been defined. In order to define these criteria, a blind 
radiological/endoscopic comparative study using endoscopy as the gold standard was 
retrospectively carried out in 72 patients. A prospective study was then carried out in 47 
patients to define the validity of the radiological criteria found by the first study. The results of 
both studies showed that the length and the width of the mucosal folds representing varices 
as measured on barium swallow radiographs have a significant relationship with the grade of 
the varices as determined by endoscopy. We conclude that barium swallow is a quick and 
reliable method for quantitative assessment of oesophageal varices.  
 
INTRODUCTION 
 
The purpose of the present study was to define a simple and reliable method for routine 
evaluation and grading of oesophageal varices. Barium swallow radiology and endoscopy 
are the methods available for the diagnosis of oesophageal varices. Endoscopy 
(oesophagoscopy) for the assessment of oesophageal varices has been performed more 
frequently in the last 10-15 years because it is easily available. This development has also 
been stimulated by the results of studies suggesting endoscopy to be superior to radiological 
examination (Conn et al, 1961). Although endoscopy is a relatively safe procedure, it is still 
associated with a small morbidity and mortality (Hart & Classen, 1990). A major 
disadvantage of endoscopy is that the interpretation is subjective and often based on non-
quantitative data. Several studies have been published showing a significant interobserver 
variation and lack of objectivity in the classification of oesophageal varices (Conn et al, 1961, 
1965; Theodossi et al, 1984; Bendtsen et al, 1990). The problems of endoscopic 
interpretation and grading are further enhanced by the various endoscopic grading systems 
that are being used (Dagradi, 1972; Oberhammer et al, 1978; Japanese Research Society 
for Portal Hypertension, 1980; Bendtsen et al, 1990). Another disadvantage of endoscopy is 
its high cost; a particular problem in the light of the emerging need for annual assessment 
now that prophylactic treatment for oesophageal varices is becoming available (North Italian 
Endoscopic Club, 1988; Hayes et al, 1990; Cales et al, 1990). Barium swallow for 
assessment of oesophageal varices is safe and quick to perform, can easily be repeated and 
is acceptable to almost all patients. Since no reliable objective radiological criteria have so 
far been employed for the grading of varices, we decided to carry out a blind retrospective 
study in order to define objective radiological criteria, using endoscopy as the gold standard. 
Subsequently a prospective study was carried out to determine the validity of the newly 
identified criteria.  
Diagnosis of oesophageal varices 
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MATERIALS AND METHODS 
 
Patient groups 
First study (training sample). This group consisted of 72 patients (mean age (sd) 45 years 
(12)) who were scored blindly on barium swallow without any prior information about the 
results of the endoscopic examinations. All patients were suffering from chronic liver 
disease of various aetiology and severity, and were not selected with regard to sex or age. 
The endoscopic examination of the oesophagus took place within three months of the barium 
swallow. The results of the radiological assessment were compared with the endoscopic 
findings, and quantitative criteria (see below) for the radiological grading of varices were 
subsequently defined using the endoscopic grading as the reference method. 
 
Second study (evaluation sample). This group consisted of 47 patients who were studied 
prospectively, using the radiological method and criteria derived from the first study in order 
to validate the newly determined criteria. This group also had endoscopy within three months 
of barium swallow.  
 
Method of barium swallow 
A fasting state was not required. No premedication was given. We used a high-density 
barium sulphate (EZ.HD 250% wt/vol from EZEM Westbury Co., New York) for good coating 
of the oesophagus mucosa. To enhance filling of the varices, the Müller manoeuvre was 
used which consists of forced inspiration against a closed glottis. Mucosal relief views were 
taken 15-20 s after passage of barium bolus, with the oesophagus in a relaxed state. A total 
of six views were usually taken, all in the horizontal position: prone with head end of the table 
in 20-30° Trendelenburg as well as supine and both oblique views. Views in double contrast, 
and filled and overdistended views were avoided since they tend to efface the varices. 
Gastric varices were occasionally seen, but no attempt was made to measure or classify 
these as part of this study.  
Parameters used for evaluation of barium swallow  
Length. The length of the varices was measured on the radiographs in centimetres. The 
highest level to which the varices in the oesophagus could be visualized was taken as the 
proximal limit and the level just above the oesophagogastric junction as the distal limit 
(Figures 1,2). 
Width. The maximum width of the mucosal folds representing varices was measured in mm 
on the radiographs (Figures 1,2). All the measurements were carried out directly on the 
radiographs and no corrections for magnification were made. 
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Figure 1: Barium swallow with application of Müller manoeuvre. (a) Parallel folds 2 mm wide in the 
upper part with some thickened folds and slight turtuosity in the most distal region suggestive of 
dubious or small varices. (b) A patient with ‘small’ varices (length 6 cm, width 4 mm) in distal 
oesophagus.   
Figure 2: Two patients with 'large' varices with very tortuous folds. (a) Length of varices 22 cm, width 
11 mm. (b,c) Length of varices 25 cm, width 15 mm. 
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Tortuosity. Some degree of subjectivity is impossible to exclude when examining this 
parameter. The tortuosity of the folds was defined as: no tortuosity ( -), slight ( + ), moderate ( 
+ + ) and severe ( + + + ) (Figures 1,2). 
 
Endoscopic examination 
The patients were investigated by one of four endoscopists, using flexible Olympus® 
endoscopes. The endoscopist reported the findings in a standardized way, according to 
Paquet's classification (Oberhammer et al,1972) as follows: 
Grade 0:  no varices 
Grade I:  venectasia, disappearing with insufflation 
Grade II:  larger, clearly visible, usually straight varices, not disappearing with 
insufflation 
Grade III:  more prominent varices, locally coil-shaped and partly occupying the lumen 
Grade IV:  tortuous, sometimes grape-like varices occupying the oesophageal lumen. 
Grades 0 and I were grouped together into one group (A) with no varices or small varices 
and the Grades II, III and IV were grouped together as larger and large varices (B). 
 
Statistical methods 
A multivariate logistic regression analysis (Cox, 1970) in the training sample (first study) was 
used to discriminate between absent or small varices (Grades 0 and I in Group A) and large 
varices (Grades II, III and IV in Group B). This approach was chosen because from a clinical 
point of view, the distinction between absent or very small varices and large(r) varices was 
considered relevant, particularly as the chance of bleeding from varices increases with their 
size and is virtually nil in Grade I varices. The a priori probability in this analysis was taken as 
the prevalence of large varices, i.e. 39/72 (54%). The p-values given are two-sided with 0.05 
taken as the limit of statistical signficance. 
 
RESULTS 
 
Out of the 72 patients in the first study (training sample), 33 cases had endoscopically absent 
or small varices (Group A: 19 Grade 0, 14 Grade I), while 39 cases had larger varices (Group 
B: 11 Grade II, 18 Grade 111, 10 Grade IV). Using multivariate regression it appeared that 
the length and width of the varices as measured on barium swallow were the most important 
parameters in discriminating between smaller and larger varices as classified by endoscopy. 
Although large varices were associated with a greater tortuosity (Mann-Whitney's test: p < 
0.001) than smaller varices, this parameter did not provide further discriminating power when 
both the radiological length and width were known. In Figure 3 the length and the width of the 
varices as assessed by barium swallow are plotted. Open circles represent Group A patients 
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with varices endoscopically diagnosed as Grades 0 or I, and closed circles, Group B patients 
with endoscopic Grades II, III or IV varices. Taking a line corresponding to a 50% probability 
of large varices in the plot of length versus width, (Figure 3), 5 of the 39 cases with large 
varices were situated below the line. The percentage of false negative outcomes is therefore 
13 (5/39). Of the 33 cases with smaller varices, 5 were situated above the line.  
The percentage of false positive outcomes is therefore 15 (5/33). The corresponding 
percentages for sensitivity and specificity were respectively 87% and 85%. In the second 
study of 47 patients (evaluation sample), 27 cases had no varices or smaller varices on 
endoscopy (Group A, 17 Grade 0, 10 Grade I) and 20 patients had large varices (Group B, 
10 Grade II, 7 Grade 111, 3 Grade IV). The percentages of false positive/negative outcomes 
obtained in this second group were comparable with those in the first group (Figure 4). The 
sensitivity and specificity were respectively 80% and 82%. 
 
Diagnosis of oesophageal varices 
Figure 3: Radiological length vs. width for small or no endoscopic varices (open circles) or medium to 
large varices (closed circles). The line (length 23.9 – 2.5 x width) corresponds to a 50% chance of 
larger varices. Total number of patients = 72. 
 
 
 
 
 
 
Figure 4: Radiological length vs. width for small or no endoscopic varices (open circles) or medium to 
large varices (closed circles). The line (length 23.9 – 2.5 x width)  corresponds to a 50% chance of 
larger varices. Total number of patients = 47. 
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DISCUSSION 
 
Oesophageal varices were first demonstrated radiologically as early as 1928 by Wolf. 
Schatzki also demonstrated varices in 1931. Bediczka and Taschakert described the 
classical radiographic appearances of varices in 1932 and their description basically still 
holds true. The advent of the flexible endoscope and the availability of endoscopic services 
have led to an increased preference for endoscopy in the last 10-15 years. This, however is 
not totally based on objective criteria. The major advantage of endoscopy over barium 
radiology is the ability to local vessel wall abnormalities and colour changes, particularly 
several types of red spots (Japanese Research Society for Portal Hypertension, 1980). 
Endoscopy is however invasive and involves a low morbidity and mortality rate (Hart & 
Classen, 1990). In spite of an endoscopic classification for varices, subjectively still appears 
to play an important role and leads to significant interobserver variation (Hart & Classen, 
1990; Bendtsen et al, 1990). Since it is impossible to enlist any provocative manoeuvres 
such as Müller or Valsalva in order to enhance the visibility of varices, smaller varices might 
be missed during endoscopy. Barium swallow, however, is non-invasive, cheaper than 
endoscopy, and requires no specific preparation or premedication. We did not find that 
hypotonia of oesophagus achieved by Buscopan injection as used by e.g. Dalinka et al 
(1972) improved the demonstration of varices and we therefore used no premedication or 
hypotonic agents during the radiological procedure. Barium swallow is quick to perform and 
there is virtually no risk of complication. In our experience the procedure was acceptable to 
all patients. A barium swallow also forms a permanent record of the state of the varices, thus 
permitting reliable follow-up and multicentre studies. In view of increasing interest in 
prophylactic treatment of oesophageal varices, barium swallow may be a simple and reliable 
method for yearly screening as well as for long-term follow-up of patients considered to be at 
risk of bleeding. The present study was carried out to define objective, quantitative 
radiological criteria for grading oesophageal varices. The results were compared with routine 
endoscopic examinations. Using multivariate regression analysis, it appears that the length 
and width of varices as measured on the radiographs were adequate criteria for 
discrimination between absent or small (Group A, Grades O and I) varices and larger (Group 
B, Grades II, III and IV) varices as seen by endoscopy. This was confirmed when the results 
of the first (retrospective) study were found to be reproduced in the second (prospective) 
study.  
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ABSTRACT 
 
Objective: The best known indicator of risk for first bleeding in patients with cirrhosis without 
previous bleeding is the index devised by the North Italian Endoscopic Club for the Study 
and Treatment of Esophageal Varices (NIEC index), which results from the combination of 
size of esophageal varices, severity of red wale marks, and Child-Pugh class. Its efficiency is 
far from optimal, and validation studies have reported sensitivities and specificities markedly 
lower than those reported in the original study. In the present study we analyzed the 
efficiency of NIEC index in a large series of cirrhotic patients with varices without previous 
bleeding. In addition, we tried to improve the effectiveness of the index by modifying it, and to 
validate the modifications in an independent group of patients. 
Methods: A total of 627 patients were enrolled and followed until either a variceal bleeding or 
for a maximum of 2 yr. During this time, 117 experienced a first variceal bleeding. 
Results: Using Cox's regression analysis, size of varices, severity of red wale marks, and 
Child-Pugh score were significant and independent predictors of first bleeding, as already 
noted in the original report of the NIEC group. However, coefficients and standard errors 
were markedly different, and the importance of size of esophageal varices in the regression 
was much larger, whereas that of Child-Pugh score was much lower. According to these 
data, a revised index was developed (Rev-NIEC). Using receiver operating characteristic 
(ROC) curve analysis, the revised index showed a larger efficiency, and the area under the 
curve was significantly larger (0.80 ± 0.02 vs 0.74 ± 0.02; p < 0.01). In particular, the curve 
showed that for a specificity of 75%, the new index had a sensitivity of 72% compared to that 
of 55% of the NIEC index. Validation in an independent sample of 84 patients showed good 
agreement between predicted and observed risk for bleeding. Validation with the bootstrap 
technique also showed adequate stability of the results. 
Conclusions: The revised index seems to be superior to the traditional index, and may turn 
out to be more useful in the selection of patients for different therapeutic procedures and in 
the stratification of patients in clinical trials. (Am J Gastroenterol 2000;95:2915-2920. ©2000 
by Am. ColI. of Gastroenterology) 
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INTRODUCTION 
 
Prediction of the first variceal bleeding in patients with cirrhosis and esophageal varices has 
been a clinically relevant problem for hepatologists for a long time. Indeed, an accurate 
prognostic evaluation is the basis for all effective strategies to prevent a first variceal 
bleeding. Unfortunately, available indicators of risk for bleeding are far from optimal. The 
most widely used of them is the index of the North Italian Endoscopic Club for the Study and 
Treatment of Esophageal Varices (NIEC index) (1), which results from the combination of 
size of esophageal varices, severity of red wale marks, and Child-Pugh class (2). Its 
prognostic efficiency is rather limited: indeed, when a 78% sensitivity is requested, specificity 
is only 51 %; conversely, when 88% specificity is requested, sensitivity is only 38% (3). In 
addition, validation studies in independent samples showed sensitivities and specificities 
definitely lower than in the original report (4, 5) (Fig. 1 ). This may be due, at least in part, to 
the expected decrease in efficiency of all indexes when applied in different samples (6).  
For these reasons we aimed to do the following: 1) to assess the efficiency of NIEC index in 
a large series of cirrhotic patients with varices without previous bleeding; 2) to try to improve 
the efficiency by deriving possible modifications according to statistical analyses; and 3) to 
validate the modifications in a further group of patients followed in a different country . 
 
MATERIALS AND METHODS 
 
Clinical, biochemical, and endoscopic data of 627 cirrhotic patients with esophageal varices, 
without previous variceal bleeding, and without treatment for portal hypertension were 
collected. All patients were taking part in studies of natural history of portal hypertension, 
performed in the past years in the Clinica Medica V and Centro di Spleno-Epatologia of the 
University of Padua ( 146 patients), the Clinica Medica II of the University of Bologna (326 
patients), and the Department of Clinical Medicine and Gastroenterology of the University of 
Bologna (155 patients). Patients included in Padua had been included in a study of natural 
history of cirrhotics with varices without previous bleeding (7) or were a subgroup of a series 
of patients included in a study on the prognostic value of hemodynamic evaluation of portal 
hypertension (8). Patients followed in the Department of Internal Medicine, Cardioangiology, 
Hepatology of the University of Bologna were included in a validation study of the Italian 
Liver Cirrhosis Project on classification of esophageal varices (9); patients followed in the 
Department of Clinical Medicine and Gastroenterology of the University of Bologna were 
included in a prospective evaluation of duplex-Doppler ultrasonography in the prediction of 
variceal hemorrhage (10).  
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The protocols were approved by the Ethical Committees, and informed consent was obtained 
from all subjects. The main demographic, clinical, and biochemical data of investigated 
patients are reported in Table I. 
Patients were periodically seen in the outpatient clinics, and were admitted to the hospital 
when clinically requested; they were considered in the follow-up until a first variceal bleeding, 
until death, or for up to 2 yr. During this period 119 patients had a variceal bleeding. Bleeding 
was considered to be arising from varices if a bleeding varix or a fibrin clot was seen at 
emergency endoscopy or when varices were the only potentially bleeding lesions. In the 18 
cases in which emergency endoscopy could not be done, bleeding was considered to be 
arising from varices, as this is the most frequent source. To validate the NIEC index, it was 
calculated in individual cases, and a receiver operating characteristic (ROC) curve describing 
sensitivity and specificity in predicting bleeding for the different values of the NIEC index was 
built using seven equally spaced cut-off points. Area under the ROC curve (AUC), 
expression of the overall efficiency of the index in predicting bleeding, was calculated 
according to Hanley and McNeil (11). The larger the area, the more efficient the index is in 
predicting bleeding. With the aim of improving prognostic efficiency of NIEC index, possible 
significant variables related to first variceal bleeding were searched univariately drawing 
Kaplan-Meier plots (12); variables that turned out to be significant and proportionally spaced 
with time were tested in a multiple regression model according to Cox (13). In this way a set 
of significant variables independently linked to the risk for bleeding was obtained, and from 
them a prognostic index was developed (Rev-NIEC). 
 
Figure 1. Receiver operating characteristic curve of the prediction of a first variceal bleeding according 
to the North Italian Endoscopic Club (NIEC) index in the original sample (triangle), and in the 
validation studies by Prada et al. (ref. 4) (x), and by Rigo et al. (ref. 5) (+). 
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Table 1. Main Clinical, Biochemical, and Endoscopic Data for the 627 Patients With Cirrhosis 
Age (yr)    58 ± 11 
Sex     Male = 311   Female = 317 
Etiology    Alcoholic = 331  Nonalcoholic = 296 
Ascites    Absent = 407   Present = 220 
Hepatic encephalopathy  Absent = 566   Present = 61 
Esophageal varices   F1 = 299   F2 = 229    F3 = 99 
Red wale marks   Absent = 288   1 + = 200;  2+ = 115   3+ = 24 
Serum albumin (g/dl)   3.46 ± 0.54 
Serum bilirubin (mg/dl)   2.17 ± 2.33 
Prothrombin activity (%)  65 ± 15 
Child-Pugh score   7.4 ± 2.0 
Child-Pugh class   A = 263   B = 259    C = 105 
 
According to this index a ROC curve was built clustering values in seven equally spaced 
classes. The AUC according to Rev-NIEC was calculated and was compared to the AUC 
obtained according to the original NIEC index, using the method described for the 
comparison of AUCs obtained from the same data (14). 
To validate Rev-NIEC, a series of 84 patients with varices and without previous variceal 
bleeding (who were a control group in a clinical trial of sclerotherapy performed at the 
Division of Internal Medicine, Dijkzigt Hospital, University of Rotterdam, The Netherlands) 
was considered (15). Patients were comparable for clinical and biochemical characteristics 
and for observed rate of first variceal bleeding (17 patients in 24 months = 19.5%). In 
particular, esophageal varices were classified as Fl in 35 patients, F2 in 33, and F3 in 16. 
Red wale marks (RWM) were absent in 46 patients, 1+ in 20, 2+ in 16, and 3+ in two. Child-
Pugh class was A in 47 patients, B in 29, and C in eight. Rev-NIEC was calculated in the 
single patients of the validation group, and a ROC curve describing sensitivity and specificity 
of the prediction of a first variceal bleeding within 2 yr was built. The AUC for this ROC curve 
was calculated and was compared to that obtained in the group of 627 patients using the 
method described to compare AUCs obtained in different groups of patients (11). A further 
validation was performed according to the boot-strap technique (16). The model was 
reanalyzed on 20 repeat samples of 313 randomly selected cases of the data set, and the 
coefficients of variation of the obtained β-coefficients were calculated. This method of internal 
validation assesses how accurately the model is able to predict the outcome in a new, similar 
sample of cirrhotic patients. The whole statistical analysis was performed with the BMDP 
statistical software (Los Angeles, CA) (17). 
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Figure 2. receiver operating characteristics curve of the prediction of a first variceal bleeding according 
to the North Italian Endoscopic Club (NIEC) index in the original sample (triangle), and in the present 
series of 627 patients (boxed x]). 
 
RESULTS 
 
Validation of the NIEC Index  
The ROC curve built with the present series according to the original NIEC index is shown in 
Figure 2. Its AUC was not significantly different from that built with the cases reported in the 
original publication of the NIEC group (1); indeed, it was marginally larger (0.74 ± 0.02 vs 
0.71 ± 0.02; p = NS). 
 
Revision of the NIEC Index 
On univariate analysis, the probability of variceal bleeding was significantly higher in patients 
with larger esophageal varices (Mantel-Cox test = 159.8; p = 0.0001), with more severe red 
wale marks (Mantel-Cox test = 90.9; p = 0.0001), or with more severe liver dysfunction 
according to the Child-Pugh classification (Mantel-Cox test = 9.9; p = 0.007). According to 
the multiple regression analysis, the three variables were significant independent predictors 
of risk for bleeding (Table 2). Considering that the ratios between coefficients and their 
standard errors represent the relative weight in the regression, it seems that the variceal size 
is the most important predictor, and that the weight of Child-Pugh score is rather limited. 
From regression coefficients, a prognostic index (Rev-NIEC) was built according to the 
formula: 
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Rev-NIEC = (1.12 X F) + (0.36 X RWM) + (0.04 X Pugh), where F is the size of varices 
according to the Beppu' s classification (values from 1 to 3), RWM is the severity of RWM 
(values from 0 to 3), Pugh is the Child-Pugh score (values from 5 to 15). Sensitivities, 
specificities, and predictive values according to various cut-offs of the two classifications 
(NIEC and Rev-NIEC) are reported in Table 3. 
The ROC curve built from Rev-NIEC values had a significantly higher AUC than that built for 
the same patients according to the original NIEC index (0.80 ± 0.02 vs 0.74 ± 0.02; z = 5.00; 
p < 0.01). In particular, for a specificity of 75%, the revised index had a 72% sensitivity 
compared to the 55% sensitivity of the original index in predicting bleeding (Fig. 3). 
 
Validation of the Revised Index 
Internal validation using the bootstap technique gave reasonable stability of the coefficients: 
indeed, in 20 random samples each containing 50% of the original series, the mean β-
coefficients for the three selected variables, calculated according to the Cox regression 
analysis, were nearly identical to those of the whole series (1.14, 0.36, and 0.08) for size of 
varices, red wale marks, and Child Pugh score, respectively, and the coefficient of variation 
was 0.14, 0.34, and 0.35, respectively.  
 
Table 2. Cox Multiple Regression Analysis of Variables Predicting Gastrointestinal Bleeding 
 
Variable  β-Coefficient  SEM  β -Coefficient/SEM  95% CI for β Increase in X2  p 
value 
Size of varices   1.12  0.14  7.53    0.85-1.39  119.3             0.0001 
(cm) 
Red wale marks  0.36  0.11  3.40    0.14-0.58  11.4   0.001 
Child-Pugh score  0.08  0.04  1.69    0.02-0.150  2.9   0.09 
CI = confidence interval; SEM = standard error of the mean. 
 
Validation of Rev-NIEC in the 84 patients followed in Rotterdam demonstrated that 
prognostic efficiency is maintained when applied to patients different from those in whom the 
index was developed. Indeed, the ROC curve built with validation cases had an AUC slightly 
smaller than that built from the original data, as expected; but the difference between the two 
AUCs was not significant (0.75 ± 0.06 vs 0.80 ± 0.02; z = 0.79; p = NS) (Fig. 4). 
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Figure 3. Receiver operating characteristic curve of the prediction of a first variceal bleeding in the 
present series of 627 patients according to the North Italian Endoscopic Club (NIEC) index (boxed x) 
and to the revised NIEC index (Rev-NIEC) (inverted triangle).  
 
Table 3. Sensitivity, Specificity, and Predictive Values of the Original and Revised NIEC Classification 
in Prediction of Bleeding in the 627 Patients 
                                                                                                                  +Predictive        -Predictive 
Classification   Sensitivity   Specificity   Value   Value 
NIEC 
>20    0.96    0.22    0.22   0.96 
>25    0.89    0.44    0.27   0.94 
>30   0.74    0.64    0.33   0.91 
>35    0.41    0.82    0.35   0.85 
>40    0.18    0.96    0.52   0.83 
Rev-NIEC 
>1.75    0.96    0.27    0.24   0.97 
>2.50    0.88    0.54    0.31   0.95 
>3.25    0.71    0.77    0.42   0.92 
>4.00    0.45    0.93    0.60   0.88 
>4.75    0.16    0.98    0.66   0.84 
NIEC = North Italian Edoscopy Club index; Rev-NIEC = revised NIEC index. 
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DISCUSSION 
 
In the present study, we tried 1) to validate the use of NIEC index to predict the first variceal 
bleeding in cirrhosis; 2) to suggest a possible improvement; and 3) to validate the 
improvement in an independent series of patients. The analysis of the course of the group of 
627 patients followed in Padua and Bologna showed that NIEC index is an effective indicator 
of risk for bleeding. Previous validation studies (4-5) only reported that NIEC index was able 
to discriminate groups with different outcomes in series different from that in which the index 
was developed, but a formal statistical validation with ROC curve and AUC comparisons has 
never been reported. Drawing the ROC curves from the data of the two previous validation 
studies allowed us to show that in the previous reports the sensibility and specificity was 
lower than expected (Fig. l). At variance, in our group the index had an adequate 
performance, keeping the sensitivity and specificity observed in the series in which it was 
developed. The value of the present observation is reinforced by the fact that our series is 
larger than the sum of the two other validation studies (4, 5), and that patients were followed 
in different centers. Despite the good prognostic efficiency of NIEC index observed in the 
present series, we were able to suggest an improvement of the NIEC index. Indeed, using 
the Cox regression analysis we confirmed that size of varices, extent of RWM, and severity 
of liver dysfunction (Child-Pugh classification) are independent predictors of variceal 
bleeding, as first reported by the NIEC group (I); but a better prognostic efficiency may be 
obtained modifying the coefficient, and giving a larger weight to size of varices, and less to 
the Child- Pugh classification. The confidence limits of the β-coefficients in the present 
regression analysis are rather different from those in the original NIEC report (1) and are not 
compatible with repeat variability. The relative weight of the various component in the 
regression equation may be derived from the ratio coefficient to the SE of the coefficient (18). 
The larger the ratio, the larger the weight of the variable in the overall prediction. In the report 
of the NIEC group the exact values of the ratios coefficient to SE are not stated, but the 
points to add in the pocket chart demonstrate that the weight of Child-Pugh class is only 
marginally smaller than that of variceal size. At variance, in the present series the weight of 
variceal size was nearly five times that of Child-Pugh score. This implies that, according to 
the original NIEC index, a patient with Fl varices and Child-Pugh class C has approximately 
the same bleeding risk as that of a patient with F3 varices and Child-Pugh class A, whereas, 
according to our revised index, the latter has a much higher risk. This modification was 
associated with a significant change in prognostic efficiency, from 74% to 80%. Such a 
modification seems reasonable because all prognostic studies agree on the importance of 
variceal size (8, 10, 19,20), although contrasting evidence is available on the importance of 
the severity of liver dysfunction in predicting variceal bleeding (21).  
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The difference in efficiency between the NIEC and the revised indexes is particularly evident 
in conditions of elevated risk, in which, for a given specificity value (e.g., 75% ), sensitivity is 
increased (e.g., from 55% to 72%; i.e., 17 additional patients for every 100 patients are 
correctly classified as bleeders within the next 2 yr) (Fig. 3). 
A new prognostic indicator usually seems to be excellent in those patients in which it was 
developed, as the typical pattern of covariates of patients considered in the study are used to 
define the indicator itself; conversely, it shows a tendency to perform less well in validation 
studies (6, 22). From these considerations, the need arises to validate all prognostic indexes 
in different series. In the present study, the validation group collected in The Netherlands had 
a clinical course very similar to that predicted, and the efficiency of the revised index was 
confirmed, as the AUCs were not significantly different (Fig. 4). In addition, the internal 
validation with the bootstrap technique showed steady values for model parameters, 
confirming the validity and robustness of the model. It might be suggested that the difference 
between the present model and that underlying NIEC index is only caused by repeat 
variability, i. e., random variability of the observed series of patients. Nevertheless, the 
confidence intervals for the coefficients related to variceal size in the regression (coefficient ± 
1.96 X SEM, i.e., 0.85-1.39) seem rather far from the value of 0.645 described in the original 
report of the NIEC group (1), which was never observed in any of the 20 repeated 
subsamples of the data set containing half of the series, analyzed according to the bootstrap 
technique.  
In conclusion, the NIEC index is an adequate and a validated instrument for predicting first 
variceal bleeding, but its efficiency may be increased by a modification in the coefficients, 
giving a larger weight to size of varices and decreasing that of Child-Pugh class. This 
modification seems to be stable, inasmuch as it was validated in an independent sample. 
This revised index is suggested for the selection of patients to be treated and for stratification 
in clinical trials.  
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Figure 4. Validation of the revised North Italian Endoscopic Club (NIEC) index: absence of significant 
difference between receiver operating characteristics curves obtained in the 627 patients of the 
training sample collected in Padua and Bologna (inverted triangle) and the 84 patients of the test 
sample collected in Rotterdam (x). 
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SUMMARY 
 
Background: Since esophageal variceal bleeding is associated with a high mortality rate, 
prevention of bleeding might be expected to result in improved survival. The first trials to 
evaluate prophylactic sclerotherapy found a marked beneficial effect of prophylactic 
treatment. These results, however, were not generally accepted because of methodological 
aspects and because the reported incidence of bleeding in control subjects was considered 
unusually high.  
Objective: To compare endoscopic sclerotherapy (ES) with a medical regimen for the primary 
prophylaxis of esophageal variceal bleeding in patients with cirrhosis. 
Methods: 166 patients with esophageal varices grade II, III of IV according to Paquet’s 
classification, with evidence of active or progressive liver disease and without prior variceal 
bleeding, were randomized to groups receiving ES (n=84) or no specific treatment (n=82). 
Primary end-points were incidence of bleeding and mortality; secondary end-points were 
complications and costs.  
Results: During a mean follow-up of 32 months variceal bleeding occurred in 25% of the 
patients of the ES group and in 28% of the control group. The incidence of variceal bleeding 
for the ES and control group was 16% and 16% at 1 year and 33% and 29% at 3 years, 
respectively. The 1-year survival rate was 87% for the ES group and 84% for the control 
group; the 3-year survival rate was 62% for each group. In the ES group one death occurred 
as a direct consequence of variceal bleeding compared to 9 in the other group (p=0.01, log-
rank test). Complications were comparable for the two groups. Health care costs for patients 
assigned to ES were estimated to be higher.  Meta-analysis of a large number of trials 
showed that the effect of prophylactic sclerotherapy is significantly related to the baseline 
bleeding risk.  
Conclusion: In the present trial, prophylactic sclerotherapy did not reduce the incidence of 
bleeding from varices in patients with liver cirrhosis and a low to moderate bleeding risk. 
Although sclerotherapy lowered mortality attributable to variceal bleeding, overall survival 
was not affected. The effect of prophylactic sclerotherapy seems dependent on the 
underlying bleeding risk. A beneficial effect can only be expected for patients with a high risk 
for bleeding.  
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INTRODUCTION 
 
About one-third of patients with liver cirrhosis and varices are likely to undergo hemorrhage 
during their lifetime (1-5). The average mortality due to the first variceal bleeding has been 
estimated to be about 30-50% (1, 6, 7). Variceal bleeding therefore represents a frequent 
cause of death and one might expect survival to improve if bleeding could be prevented.  
The potential of primary prevention of variceal bleeding to improve prognosis is dependent 
on the severity of the underlying disease. There is a close relationship between (risk of) 
bleeding and degree of liver failure. Often bleeding precipitates or exacerbates liver failure, 
while deteriorating liver function frequently precedes variceal bleeding. Obviously, prevention 
of bleeding in end-stage disease is unlikely to affect prognosis. For patients with a relatively 
preserved liver function, however, prevention of bleeding might improve prognosis, by 
reducing mortality due to exsanguination as well as from the complications frequently 
encountered after variceal bleeding, including hepatorenal syndrome, infections and multi-
organ failure.  
The first type of primary prophylaxis evaluated was the portacaval shunt (3-5). Although 
shunt surgery reduced the frequency of bleeding, the rate of both mortality and 
encephalopathy was increased. Data on other prophylactic surgical procedures are limited 
and do not allow conclusions (8).   
The first reports on the use of prophylactic sclerotherapy suggested that this procedure not 
only significantly reduced the incidence of variceal bleeding (9-12) but also lowered overall 
mortality (10, 12). However, the results of these trials were disputed, mainly because the 
reported bleeding risk for control patients in some studies was considered exceptionally high 
and treatment of acute variceal bleeding episodes was not the same for the two treatment 
groups (1, 13). 
The aim of the present multicentre study was to evaluate the effect of endoscopic 
sclerotherapy for the primary prevention of variceal bleeding in an adequate number of 
patients with cirrhosis and esophageal varices, with uniform treatment of variceal bleeding in  
both groups.    
 
PATIENTS AND METHODS  
 
Patient selection 
Eligible patients were adults with endoscopically documented grade II, III or IV esophageal 
varices (14), absence of prior bleeding from varices, evidence of active and/or progressive 
liver disease (e.g. as indicated by repeatedly elevated serum transaminases or increasing 
serum bilirubin levels or development of ascites within the past year) or documented 
increase in the size of esophageal varices; all patients gave informed consent.   
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Patients were excluded for the following reasons: malignancy, hemophilia, age older than 70-
75 years, no opportunity for follow-up visits.   
 
Centers, study design, randomization and informed consent 
This was a multicentre randomized controlled trial that started on 1 May 1986. Patients were 
included until May 1993 and followed until November 1993. Participating centers (number of 
patients in parentheses) were the University Hospital Rotterdam (coordinating center)(81); 
the University Hospital Utrecht (25); the Zuiderziekenhuis, Rotterdam (17); the Academic 
Medical Center, Amsterdam (15); the Ziekenhuis Leyenburg (12) and Westeinde Hospital 
(10), The Hague; and the Reinier de Graaf Gasthuis, Delft (6).   
Randomization was performed according to Zelen’s pre-randomization design (15). After 
assessment of eligibility, patients were randomized and provided with oral and written 
information; they were then asked to participate and give informed consent. This procedure 
was expected to facilitate patient entry, being considered defensible and appropriate taking 
into account the marked difference between the two treatment options (16). The medical 
ethical committee of one center did not approve of the pre-randomization method; in this 
center the conventional procedure was followed.   
Treatment was assigned centrally, by telephone contact or by visiting the trial office, using 
opaque, serially numbered, sealed envelopes. Patients were stratified for center and severity 
of liver disease according to the Child-Pugh classification (17). Follow-up started at the time 
of randomization. Patients gave written informed consent. The medical ethical committees of 
the participating centers approved the trial.  
 
Endoscopic sclerotherapy 
Experienced endoscopists performed all procedures using fiber or video-endoscopes. 
Patients received intravenous sedation consisting of 0.075 – 0.2 mg midazolam/kg. Varices 
were injected at multiple sites with 0.5-3 ml ethoxysclerol (polidocanol) 1% or 2% (Kreussler, 
Germany), proceeding upwards from the gastroesophageal junction. The maximum injection 
volume was 35 ml/session. Patients were hospitalized for the first sclerotherapy session. 
Successive treatments were planned on an outpatient basis at 3-week intervals until variceal 
obliteration was achieved. The aim of sclerotherapy was complete variceal eradication. 
Subsequently control examinations were performed at 6-month intervals. Recurrent varices 
were treated. When eradication was established on two subsequent visits further control 
examinations were scheduled at yearly intervals.    
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Entry and follow-up procedures 
Before randomization, all patients underwent upper gastrointestinal endoscopy. Esophageal 
varices were classified according to Oberhammer and Paquet (14). Meetings of participants 
were organized to review and standardize diagnostic aspects. The Child-Pugh classification 
system (17) was used as a measure of functional hepatic reserve.  General care of the 
patients in both groups was identical and involved clinical and biochemical assessment at 3-
month intervals.    
 
Definition of key events; management of rebleeding and complications 
We used international consensus definitions of variceal bleeding and variceal rebleeding 
(18). For both groups, the standard therapy for variceal bleeding was resuscitation followed 
by endoscopic sclerotherapy according to the methods described above, but at intervals of 
one week until variceal obliteration was achieved. Subsequently, follow-up examinations 
were performed after 3 months, and then at 6, 9 and finally 12-month intervals. Balloon 
tamponade was performed when variceal bleeding was not controlled by ES for a period of 
up to 24 hours and was followed by renewed ES. Therapy for patients with persistent or 
recurrent variceal bleeding was not defined and decisions were left to the discretion of the 
individual hospital departments. Variceal obliteration was defined as variceal thrombosis and 
absence of variceal blood flow as assessed by needle puncture. Variceal eradication was 
defined as visual absence of variceal columns. Procedure-related mortality was defined as 
death within 30 days of ES. Esophageal mucosal ulcers after ES were not regarded as a 
complication unless they caused symptoms, including bleeding and pain.   
 
Analysis of costs  
An estimation of the direct medical costs was made by comparing the time spent in the 
intensive care unit and the ordinary ward, the number of visits to the outpatient department 
and the number of upper gastrointestinal endoscopies, including sclerotherapy procedures.  
Only patients admitted to the University Hospital Rotterdam were included. Indirect costs, 
e.g. economic loss due to inability to work, were not taken into consideration.  
 
Statistics 
A sample size calculation was performed assuming a 30% and 10% incidence of bleeding 3 
years after entry for the control and ES groups, respectively. To detect this difference with a 
significance level (alpha) of 0.05 and a power of 90%, and using a two-tailed test, we 
calculated that we needed to recruit 79 patients for each treatment group. Analyses were 
performed on an intent-to-treat basis. The primary end-points of this study were variceal 
bleeding and mortality. Secondary end-points were complications and health-care costs.  
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Bleeding and mortality were analyzed using the Kaplan-Meier method. Differences between 
groups were compared by means of the log-rank test. The χ2 test was used to analyze 
differences between groups for qualitative data. Paired and unpaired t-tests, or their non-
parametric equivalents where appropriate, were used for quantitative data. For analyzing the 
relationship between baseline bleeding risk and the effect of prophylactic sclerotherapy on 
the risk of a first variceal bleeding, as reported in the literature and including data of the 
present trial, the method proposed by Arends et al (19) was used. A two-tailed p-value ≤ 0.05 
was considered significant.  
 
RESULTS 
 
Of the 166 patients enrolled in the study 84 were randomized to undergo ES and 82 to the 
control group (Figure 1). Patient characteristics of the two groups were comparable (table 1). 
Mean follow-up was 32 ± SD 25 (range 0.1 – 88.5) months; for the ES group 30 ± 23 months 
and for controls 34  27 months. Follow-up was incomplete for 11 (ES group 7) patients due 
to removal, emigration or other reasons. For these cases data were censored at the time of 
the last visit. In all cases, however, efforts were undertaken to determine whether the 
patients were alive at the time of analysis and this information, including causes of death, 
was used for analysis.    
 
Procedures 
For sixteen patients assigned to undergo ES, treatment was not instituted because of refusal 
(n=13), concomitant medical problems (n=2) or miscommunication resulting in failure to 
initiate ES (n=1). ES was offered to one control patient who repeatedly expressed the explicit 
wish to be treated because of fear of bleeding. No patient refused to participate in the trial 
with respect to the prospective recording of follow-up data. During follow-up 9 patients of the 
control group and 4 of the ES group received a liver transplant. For these cases data were 
censored at the time of transplantation.  
 
Bleeding 
(Table 2) Both the number of patients and the number of episodes of variceal bleeding in the 
two groups were comparable. The same applied for bleeding due to non-variceal causes. 
The incidence of bleeding from varices (Figure 2) for the ES and control groups was 16% 
and 16% at 1 year, 29% and 29% at 3 years and 33% and 35% at 4 years, respectively (NS). 
Variceal bleeding occurred in 7 of 16 (43%) patients of the ES group who did not receive 
therapy. For 10/14 patients of the ES group variceal bleeding occurred early (mean 3.5 
months, range 1 day - 9 months), before variceal eradication had been achieved. Two of 
these patients had a variceal bleeding after randomization but before ES was started.  
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In 4 patients who had ES which resulted in variceal eradication, variceal bleeding occurred 
after a mean period of 28 months and 5.5 (range 4-9) ES sessions.  
The incidence of upper gastrointestinal hemorrhage due to all causes was 22% for the ES 
group and 25% for the control group after 1 year and 35 and 36 % after 3 years.  Per 
protocol analysis of those patients who underwent the allocated treatment showed that the 
incidence of variceal hemorrhage for the ES and control group was 17% and 14% after 1 
year and 19% and 29% after 3 years, respectively. The 1 and 2 year incidence of upper 
gastrointestinal hemorrhage due to all causes was 21% and 29% for the ES group and 15% 
and 36% for the control group, respectively (NS).  
 
Mortality 
Twenty-nine (35%) patients of the ES group died and 33 (40%) of the control group (Table 
3). In the ES group only 1 death occurred as a direct consequence of variceal bleeding 
compared to 9 in the other group (p=0.01, log-rank test). The frequency of other causes of 
death was comparable. The 1-year survival rate was 87% for the ES group and 84% for the 
control group; the 3-year survival rate was 62% for each group (figure 3). Univariate analysis 
showed that 3-year survival for Child-Pugh class A, B and C patients was 77%, 45% and 
31% (p = 0.05). No relationship was found between mortality and the size of esophageal 
varices, etiology of liver disease or participating center.  
 
Complications 
Clinical events believed to be related to previous sclerotherapy were compared between both 
treatment groups (Table 4). Although more complications were noted in the ES group, the 
difference was not significant. One fatal complication occurred in a patient of the ES group 
due to esophageal perforation after two treatment sessions. Two patients developed 
symptomatic submucosal esophageal hematomas, and in one case this complication was 
observed on two occasions. In all cases spontaneous and complete resolution ensued.  Two 
to four endoscopic dilatations were required in 3 cases of esophageal stenosis following 
sclerotherapy; in all cases the symptoms were alleviated. We found no evidence that the 
frequency of complications differed between centers. 8 /91 (9%) Child-Pugh class A patients 
suffered a complication compared to 8/57 (14%) class B patients and 1/18 (6%) class C 
patients (NS). Thus, no clear relationship was found between the risk of complications and 
the severity of liver disease. 
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Costs 
In the University Hospital Rotterdam, 299 upper gastrointestinal procedures were carried out 
in 41 patients assigned to receive ES, compared to 89 procedures for the control group 
(n=40) (p=. 0001). The mean number of days in hospital was 55 for the ES and 35 for the 
control patients (NS). The total number of days in hospital was 2277 for the ES group and 
1400 for the control group (p=0.05). The time spent in intensive care (ES group 58, controls 
48) was comparable but ES patients spent significantly more time in other wards (2219 vs. 
1352 days). The numbers of visits to the outpatient department (ES group: mean 13.4; total 
549; control group: mean 12.8; total 512) were comparable. Altogether, these data indicate 
that ES was the more expensive strategy, suggesting that the initially higher costs of 
prophylaxis due to hospital admissions and endoscopic procedures were not compensated 
by potentially decreased medical consumption over time.   
 
DISCUSSION 
 
In this randomized trial primary prevention of variceal bleeding using endoscopic 
sclerotherapy did not reduce the bleeding risk for patients with liver cirrhosis and esophageal 
varices. We found that prophylactic sclerotherapy lowered the risk of fatal variceal bleeding 
without affecting overall survival. Finally, complications and costs were more marked among 
patients receiving endoscopic prophylaxis.   
Several factors could possibly explain why sclerotherapy was not found to reduce the risk of 
variceal bleeding in the current trial. We may have failed to detect a real treatment effect, a 
type II statistical error. Although the sample size of this study seemed adequate, a type II 
error remains a realistic possibility, in particular because nearly 20% (16/84) of patients did 
not undergo the assigned sclerotherapy treatment. Since the bleeding risk for this particular 
subgroup was high, this may have diluted the beneficial effects of endoscopic prophylaxis. 
Although per protocol analysis showed a trend in favor of this possibility, it was not 
significant. Another factor that could have obscured benefits of ES is an unexpected low 
bleeding rate for the control group. However, we found that the 3-year bleeding risk for 
control patients was very similar to the predicted 30%, and consequently that this factor does 
not seem of importance.  Although this was a randomized trial, one can never guarantee 
similarity between groups as far as prognostic variables are concerned. Moreover, 
differences between groups in baseline bleeding risk could be a source of bias. The 
distribution of variables of prognostic significance in the two groups, particularly Child-Pugh 
scores, age and variceal size, however, make it unlikely that such a bias was important. 
Sclerotherapy could increase the initial risk of (variceal) bleeding but have a protective effect 
over time, eventually translating into an overall treatment benefit.  
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We found some evidence to support this possibility since the majority of variceal bleeding 
episodes were observed before achieving variceal eradication, and bleeding after eradication 
was a rare event. It has been noted previously that the bleeding risk for patients recruited for 
trials of prophylactic therapy seems highest during the first months of follow-up and 
decreases to about 1/3 after one year (1, 3). This may suggest that, in retrospect, our 
sclerotherapy protocol was not optimal and a more intensive regimen, resulting in more rapid 
eradication of varices (20), could have been more effective.  
In this trial ES significantly reduced the mortality rate for variceal bleeding, a finding also 
reported by other groups (10, 20-24). In only a few studies, however, was this associated 
with a corresponding improvement in overall survival (10, 20, 21, 24). In these studies 
variceal bleeding occurred in at least 50% of control patients and was the main cause of 
death, accounting for 65-80% of mortality. This suggests that the magnitude of the effect of 
prophylactic sclerotherapy on the risk for variceal bleeding, but also on mortality, is 
dependent on the baseline bleeding risk. This hypothesis was supported by D’Amico, who 
found a clear relationship between the effect of sclerotherapy on the incidence of bleeding 
and the base line bleeding risk as reported in a large number of randomized controlled trials 
(25). However, the Bayesian statistical method he used (26) was not optimal (19). For 
analyzing the relationship between baseline risk and treatment effect we therefore used 
another approach (19). We found, in agreement with D’Amico’s results, that a significant 
(p<0.001) relationship exists between the baseline bleeding risk and the effect of treatment 
when analyzing the results of trials of prophylactic sclerotherapy (Figure 4 and 5), which 
cannot be attributed to ‘regression to the mean’. Thus, endoscopic sclerotherapy is likely to 
reduce bleeding risk, and probably also mortality, only for patients with a particularly high risk 
of bleeding. Identification of such patients is possible using the NIEC, or comparable, indices 
(27, 28). For patients with a low bleeding risk, the effect of sclerotherapy will be marginal or 
absent; sclerotherapy might even have a deleterious effect. The numerous trials on 
prophylactic sclerotherapy have been subjected to meta-analysis (29-32). All studies have 
produced a statistically significant pooled estimate of treatment effect on bleeding risk and 
mortality in favor of sclerotherapy. Like the results of the individual studies, the conclusions 
based upon these analyses have been diverse, varying from an undetermined effect of 
sclerotherapy (30, 31) to sclerotherapy being effective, particularly for high-risk patients (29, 
32). One meta-analysis (32) yielded a marked difference in the outcome of trials according to 
the type of sclerosant used, the results clearly favoring polidocanol.  
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The general recommendation emerging from international consensus conferences (18, 33, 
34) has been that sclerotherapy should not be used for primary prophylaxis of variceal 
bleeding, mainly because of the statistically significant heterogeneity of the treatment effects 
as observed in studies, and the availability of a non-invasive and cheap alternative (non 
selective ß-blocker treatment).  
When the trial was designed the possibility existed that, as a result of the pre-randomization 
method, not all patients would accept the assigned treatment. In practice, refusal proved to 
be a more frequent problem than expected, which complicated the interpretation of results. 
However, this problem is not unique to the pre-randomization method and similar difficulties 
can occur with conventional randomization (3, 5, 35-37). Otherwise, no problems were 
encountered and our general experience was that the method worked well. Unfortunately, 
our study design did not allow us to assess whether pre-randomization indeed resulted in 
increased patient recruitment. Pre-randomization has the potential advantage that, at least in 
theory, all eligible patients will be selected while the conventional method implies that only a 
selection of eligible patients will be entered. Consequently, the results of trials using this 
allocation method may have wider applicability.  
The observed rate of complications of sclerotherapy in this study is in agreement with 
previously reported data. In some studies, however, complications were much more frequent 
(38, 39). An explanation for these divergent results remains speculative. Variations in 
technique (32), technical skill and experience with endoscopic sclerotherapy could at least 
partially account for some of the reported differences.   
Our estimation of costs was based on a proportion of patients and the results obviously are 
preliminary in nature. Nevertheless, our data suggest that prophylactic treatment was the 
more expensive option. Taking into account the other findings, the cost/benefit ratio of 
prophylactic sclerotherapy as applied in this study seems unfavorable. 
In conclusion, the present results do not support the use of sclerotherapy for primary 
prevention of variceal bleeding when patients are selected according to the criteria we used. 
Nevertheless, according to cumulative data from a large number of trials, it can be concluded 
that endoscopic sclerotherapy can result in a significant decrease in the bleeding risk and, 
probably, also in bleeding-associated mortality, but only in selected cases with a high 
bleeding risk. On the basis of lower rates of rebleeding, mortality, complications and the need 
for fewer endoscopic treatments, variceal band ligation has been shown to be superior to 
sclerotherapy for secondary prophylaxis of variceal bleeding (40). Several trials have now 
evaluated band ligation for primary prophylaxis of variceal bleeding. In most, but not all (41), 
studies band ligation significantly reduced the bleeding risk when compared to control 
patients (41-43) or administration of propranolol (44), and in one study ligation was also 
found to improve survival (43).  
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Additional studies comparing band ligation and non-selective ß -blockers are needed before 
the role of ligation for primary prevention of variceal bleeding can be defined more precisely. 
For the time being, ß-blockers remain the principal option for primary prophylaxis of variceal 
bleeding. For patients with contraindications or intolerance for ß-blockers and for those who 
are not compliant or do not respond to treatment, variceal band ligation rather than 
sclerotherapy may be considered for primary prophylaxis (45).      
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Figure 2 
Kaplan-Meier plot showing the percentage of patients free of variceal bleeding (S: sclerotherapy 
group; C: control group).  
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Figure 3 
Kaplan-Meier plot showing the percentage of surviving patients (S: sclerotherapy group; C: control 
group). Overall survival (black lines) was comparable.  Mortality due to variceal bleeding (dotted lines) 
in the sclerotherapy group was significantly lower than in the control group (p=0.01).  
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Figure 4  
Meta-analysis (19) of the effect of prophylactic sclerotherapy on the incidence of variceal bleeding. 
The trials are arranged according to the baseline bleeding risk, expressed as the odds after 
logarithmic transformation for the control groups.  
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Figure 5  
Meta-analysis (19) of the effect of prophylactic sclerotherapy on the incidence of variceal bleeding. 
Relationship between Odds ratio for bleeding and the baseline bleeding risk.  
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Table 1. Patient characteristics at entry 
           Sclerotherapy          Controls 
Characteristic     n=84   n=82 
Age      56(23-76)  55(20-72) 
Sex (M/F) (n)     46/38   49/33 
Diagnosis  
 Alcoholic liver disease   41   40 
 Hepatitis B/C    24   21 
 PBC/PSC    11   8 
 Other     24   31 
Child-Pugh class A/B/C    52/39/9           57/31/12 
Child-Pugh score    6(5-12)   6(5-13) 
Esophageal varices 
 grade II     47   42 
 grade III    38   40 
 grade IV    15   18 
 
Ascites      44   37 
                                                                  
Laboratory 
 Bilirubin (μmol/l)   27(7-429)  27(7-217) 
 Albumin (g/l)    36(18-48)  35(23-47) 
 AT-III (IE/l)    0.7(0.22-1.45)  0.7(0.24-1.32) 
 ASAT (U/l)    44.5(12-264)  49(12-373) 
 
Results are expressed as percentages and medians with ranges, unless otherwise indicated. 
Normal ranges: serum bilirubin <18 μmol/l; albumin > 37 g/l; AT-III 0.85 – 1.50 IE/l; ASAT <35 U/l 
 
Table 2.  Variceal bleeding 
                       Sclerotherapy  Controls 
                    n = 84     n = 82 
Patients 
Variceal bleeding      21 (25%)    23 (28%) 
Non-variceal bleeding      7   (8%)     7   (8.5%) 
 
Episodes 
Variceal bleeding      32      39 
     All upper GI-bleeding             48     49 
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Table 3. Causes of death 
                  Sclerotherapy        Controls 
                 n=84    n=82 
 
Variceal bleeding        1      9 
Liver failure        9      13 
Hepatocellular carcinoma      5      3  
 Other causes 
   Malignancy      2 
Infection           4      3 
Stroke            1      3 
Bleeding from duodenal ulcer        1 
Esophageal perforation1                                              1 
Other causes/unknown            6      1         
    
  Total        29      33 
 
1  complication of sclerotherapy 
 
Table 4. Complications of sclerotherapy 
          Sclerotherapy       Controls 
                 n=84    n=82 
 
Esophagus 
 Bleeding from ulcerations     2      3 
 Submucosal esophageal hematoma    2 
 Stenosis        2      2 
 Perforation        1 
 Food impaction       1 
 Dysphagia              1 
Infections 
 Bacteremia        1 
 Bacterial peritonitis      1 
 Pneumonia        1 
 
 Total         11      6 
Values are numbers of patients 
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SUMMARY 
 
Endoscopic Injection Therapy (EIT) is the treatment of choice for controlling 
oesophagogastric variceal haemorrhage. There is a need for additional injection fluids with a 
high thrombogenic potential, as the existing sclerosing agents have a failure rate of 7%-25% 
in controlling active variceal haemorrhage. The aim of our study was to assess the efficacy 
and safety of thrombin injections given during 117 EIT sessions to 72 different patients 
between 1986 and 1991. Results could be evaluated for 107 cases (26 cases with primary 
active bleeding, 81 cases bleeding from injection sites). Haemostasis was achieved in 103 
cases (96.3%). No clinical signs of intravascular coagulation were observed. Doppler-
ultrasound examination showed normal portal vein patency in all 26 cases investigated. We 
conclude that the use of thrombin as a thrombogenic injection fluid during EIT is effective, 
safe and simple. Thrombin injections may markedly enhance the efficacy of endoscopic 
treatment for variceal bleeding. 
 
INTRODUCTION 
 
Endoscopic Injection Therapy (EIT) is generally applied as a first line therapy both in 
controlling haemorrhage from oesophageal (1,2) or gastric (3) varices and in preventing 
recurrent bleeding. Several sclerosing agents, such as ethanolamin oleate, aethoxysclerol, 
sodium morrhuate, sodium tetradecyl sulphate and alcohol are in use. Success rates 
between 75% and 93% for controlling active variceal haemorrhage have been described 
using one of these regular sclerosing agents (2). This leaves a group of patients who 
continue to bleed and are in urgent need for further therapy. Another frequent problem of EIT 
is persistent bleeding from injection sites. Attempts to control this bleeding by injecting more 
sclerosant may be complicated by subsequent development of deep ulcers, perforations or 
strictures. 
There is an obvious need to enhance the efficacy of EIT by injection fluids with more 
haemostatic potential.  
Soehendra and co-workers were among the first to report on bucrylate injections; they found 
this method to be effective in stopping active haemorrhage (100% success rate) (4,5). 
Since EIT was introduced in our hospital we have used injections of a bovine thrombin 
solution to control active variceal haemorrhage or persistent bleeding from injection sites 
whenever haemostasis could not be achieved by injecting regular sclerosants. The objective 
of the current study was to assess the efficacy and safety of thrombin as a haemostatic 
injection fluid. 
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PATIENTS AND METHODS 
 
From October 1986 till July 1991 216 patients underwent 1092 treatment sessions with EIT 
at our hospital. EIT was employed either to control active variceal haemorrhage and to 
prevent rebleeding or to prevent a first episode of variceal bleeding in the context of a 
randomised clinical trial. The endoscopic findings, information on the injection treatment and 
the results of the therapy were recorded on standard forms. Data for all EIT sessions in 
which thrombin was used were analysed. The effect of the thrombin was scored as: direct 
haemostasis, haemostasis within two minutes, haemostasis achieved after two minutes and 
persistent bleeding. The location of the injection site was scored as: oesophagus, gastric 
cardia (part of the stomach 4 cm. distal from the oesophagogastric mucosal junction) and 
gastric fundus (part of the stomach above the plane through the distal border of the gastric 
cardia, the cardia region not included). In 26 cases (21 patients) Doppler ultrasound 
investigation was performed within three weeks after EIT to detect possible portal vein 
thrombosis.  
Endoscopy was performed using Olympus GIF IT, Q10 or Q20 endoscopes. Patients 
received premedication with midazolam 0.075 mg/kg and butylscopolaminebromide 40 mg iv. 
and atropin 0.5 mg im. Ethanolamin oleate 5% or aethoxysclerol 2% were used as sclerosing 
agents. Intentionally all injections were given intravariceally in boluses of 0.5-2.0 ml, with a 
maximum of 40 ml/session.  
When bleeding did not readily respond to these injections additional 1 ml boluses of bovine 
thrombin 1000 NIH-units/ml (Thrombistat®, Warner-Lambert, Amsterdam or Topostatin® 
Hoffman-LaRoche, Mijdrecht, The Netherlands) were injected intravariceally and this 
procedure was repeated as often as considered necessary.  
 
RESULTS 
 
During the study period thrombin was administered during 117 EIT sessions to 72 different 
patients. Twenty-eight (39%) patients received thrombin on more than one occasion (20 
patients twice, 8-7 patients 3-7 times). In 2 cases with massive haemorrhage thrombin was 
used as the primary injection fluid. In 25 cases thrombin was injected after injections with the 
regular sclerosants had failed to control primary active bleeding. In 84 cases thrombin was 
injected in an attempt to control haemorrhage, caused by and persisting despite EIT, using 
one of the regular sclerosing agents. Most thrombin was injected in oesophageal or gastric 
cardia varices, reflecting the sites where varices and thus bleeds are usually encountered 
(table 1). 
Table 2 shows the haemostatic effect of the thrombin injections. In the 107 evaluable cases 
in which thrombin was used to control active haemorrhage, haemostasis was achieved 103 
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times (96.3%). Haemostasis was achieved in all 13 cases where gastric fundus varices were 
involved. In four cases bleeding continued despite thrombin injections. In one of these cases 
with primary oesophageal bleeding blood loss became so severe that continuation of EIT 
was impossible and a Sengtaken tube was introduced. In the other three cases thrombin was 
injected to control EIT induced haemorrhage (on two occasions in the oesophagus, once in 
the gastric cardia). Although complete haemostasis could not be achieved, the severity of 
bleeding decreased markedly. During the study period five patients who suffered from 
uncontrollable active haemorrhage, did not receive thrombin injections. In four patients EIT 
could not be applied or continued because the view was too limited; in one patient EIT had to 
be interrupted because of restlessness. 
The mean volume of thrombin injected which resulted in haemostasis was 4.7 ml (SD 2.6, 
range 1-18). In the four cases in which haemorrhage persisted the mean volume was 9.0 ml 
(range 6-12). 
Our initial fear that heterologous thrombin injections would lead to sensibilization and thus to 
hypersensitivity reactions on repeated administration could not be substantiated. Almost 40% 
of all patients received thrombin on more than one occasion but clinically convincing adverse 
effects were not encountered. One patient suffered from a short period of dyspnoe after the 
injection of thrombin 4 ml Thrombistat® at his first EIT including thrombin. Another patient 
suffered a transient blood pressure drop following the thrombin injections (5 ml 
Thrombistat®, the sixth time this patient received thrombin. Other cases with possible 
hypersensitivity reactions were not encountered. Doppler-ultrasound to detect subclinical 
portal thrombosis has been applied after 26 sessions (21 patients) within 21 days of EIT 
(mean 8.3 days, SD 4.4, range 1-19). No evidence for portal vein thrombosis was found. The 
mean volume of thrombin injected in these cases was 4.9 ml (SD 2.7, range 1-11). During 
the in hospital stay no clinical evidence of intravascular coagulation disorders, pulmonary 
embolism or portal thrombosis was encountered.  
 
DISCUSSION 
 
Our study results show that thrombin injections are effective in both controlling active variceal 
bleeding and bleeding from injection sites. The results suggest that thrombin, used in 
addition to sclerosing agents, may improve the efficacy and safety of endoscopic treatment 
for oesophagogastric variceal bleeding. Thrombin in an attractive injection agent since, in 
contrast to sclerosants, it exerts immediate thrombogenic activity without accompanying 
inflammatory or toxic effects. The use of thrombin may minimise the need for repeated 
injections with sclerosants at the same site and thereby the risk of complications such as 
(large) ulcers, perforations or oesophageal strictures. In our experience it is rare for active 
variceal bleeding not to be stoppable with injection therapy if the bleeding point can be 
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identified; failure to control active bleeding being nearly always due to massive bleeding 
precluding such identification. Our study further indicates that injections with thrombin are 
safe, in particular as no clinical or ultrasonic evidence of splanchnic venous thrombosis or 
pulmonary embolism was encountered. Also, our initial fear for sensibilization and 
hypersensitivity reactions was not confirmed.  
Two other studies have shown that thrombin, used in low dosage and in combination with 
other sclerosants, can be an useful adjunct  to EIT (6,7). Kitano and co-workers carried out a 
prospective randomised trial in fifty cirrhotic patients with oesophageal varices to examine 
the effects of human thrombin given concomitantly with ethanolamin oleate (6). They showed 
a very low rate of active bleeding from the injection sites if thrombin was injected 
intravariceally before withdrawing the needle, compared to injections with only ethanolamin 
oleate. Adverse effects of intravasal thrombin injections were not encountered, especially no 
clinical signs of disseminated intravascular coagulation.  After thrombin administration 
prothrombin- and partial thromboplastin time, fibrinogen and platelet counts showed no 
significant changes. However, a significant higher level of fibrinogen split products was found 
following thrombin injections. These results are in accordance with the outcome of an earlier 
study on the effect of prior administration of thrombin to sodium morrhuate (8). 
The injection of (butyl) cyanoacrylate has been described as a very effective technique for 
arresting bleeding and obliterating large varices (4,5,9,10). Cyanoacrylate hardens within 20-
40 seconds under moist conditions and almost immediately in blood. Tissue adhesives must 
be handled with great care as the injecting needle or even the working channel of the 
endoscope can become obstructed (4,9,11). Also, systemic emboli to the lungs may occur 
and two cases of  cerebral infarction have been reported (12). A major advantage of 
thrombin injections is that the administration is relatively simple and requires no specific 
technical precautions. The additional use of both thrombin and tissue adhesives may be an 
important technical improvement in endoscopic therapy for variceal bleeding. For severe 
active bleeding, in particular from gastric varices, tissue adhesive injections may be the 
preferred technique. Probably, the volume of single injections should not exceed 1 ml. to 
minimise the risk for systemic dissemination. For less severe bleeding, and for persistent 
bleeding from injection sites, thrombin injections seem a more attractive therapy.  
With the introduction of agents that have immediate obliterative or thrombogenic properties 
the term ‘endoscopic sclerotherapy’ is not fully adequate. We suggest that ‘endoscopic 
injection therapy’ may be a more appropriate term.  
In conclusion endoscopic injection of thrombin, in addition to conventional sclerosants, is 
effective, safe and simple and constitutes an important extension of the endoscopic 
possibilities for treating variceal bleeding. 
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TABLE 1.    Site of thrombin administration 
  injection site   no. of sessions 
   
  1. oesophagus   64 (54.7%) 
  2. gastric cardia  34 (29.1%) 
  3. gastric fundus  12 (10.3%) 
  4. (1+2)   06 (05.1%) 
  5. (2+3)   01 (00.8%) 
 
 
 
TABLE 2.  Indications for and effects of thrombin injections for bleeding during endoscopic 
injection therapy 
INDICATION EFFECT 
thrombin as first 
agent for variceal 
bleeding 
active bleeding 
not controlled by 
conventional 
sclerosants 
bleeding caused 
by and persisting 
after conventional 
EIT 
TOTAL 
direct 
haemostasis 
0 12 28 40 (37.4%) 
haemostasis < 2 
minutes 
1 8 43 52 (48.6%) 
haemostasis > 2 
minutes 
1 3 7 11 (10.3%) 
persistent 
bleeding 
0 1 3 4 (3.7%) 
sessions per 
indication 
2 24 81 107 (100%) 
 
NOTE: Thrombin was used in 117 sessions. In 6 sessions thrombin was used to induce thrombosis in 
large non-bleeding varices. The effect of thrombin was insufficiently documented in 4 other cases 
which were excluded from analysis.
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ABSTRACT  
 
Background: First experiences suggested that Transjugular Intrahepatic Portosystemic 
Shunt (TIPS) is more effective than endoscopic sclerotherapy in the secondary prophylaxis 
of variceal bleeding but increases the rate of encephalopathy. Variceal band ligation (VBL) 
has been shown to have significant advantages over sclerotherapy.  
Objective: to compare TIPS and VBL in the secondary prophylaxis of oesophageal variceal 
bleeding in patients with cirrhosis. 
Methods: Thirty-seven patients with a first or second episode of variceal bleeding were 
randomised to undergo TIPS (n=19) or VBL (n=18). Primary end-points were incidence of 
recurrent bleeding and encephalopathy; secondary end-points were complications and costs.  
Results: During a mean follow-up of 21 months 1 episode of recurrent variceal haemorrhage 
occurred in the TIPS group and 9 episodes in 7 patients in the VBL group. The 2-year 
incidence of variceal rebleeding was 7% in the TIPS group and 40% in the ligation group 
(p=0.03). Mortality directly associated with variceal rebleeding was not observed. The 
incidence of encephalopathy at two years was 55% in the TIPS group and 23% in the VBL 
group (NS). No difference was found in the frequency of other complications. The two-year 
survival rate was 61% in the shunted group and 76% in the ligation group (NS). Health care 
costs for patients assigned to TIPS were estimated to be higher.   
Conclusions: TIPS was superior to VBL for the secondary prophylaxis of haemorrhage in 
patients with cirrhosis and a first or second episode of variceal bleeding. This small study 
further suggests that TIPS has no marked beneficial effect on survival and is unlikely to be 
more cost-effective than VBL.  
 
INTRODUCTION 
 
During the last decades of the last century endoscopic sclerotherapy and β-blockers were 
used as the primary treatments in the secondary prevention of bleeding from varices in 
patients with cirrhosis. With the introduction of the transjugular intrahepatic portosystemic 
shunt (TIPS) into clinical practice in 1988, a new and promising therapeutic modality became 
available for treating patients with this most feared complication of portal hypertension. The 
first uncontrolled observations indicated superior efficacy with respect to prevention of 
rebleeding when compared with β-blocker treatment and endoscopic sclerotherapy, and 
lower procedure related complications and mortality compared with surgical shunts [1, 2]. 
Recognised disadvantages of TIPS were the increased risk for encephalopathy, a 
complication inherent to all shunting procedures in portal hypertension, and the high revision 
rate for shunt dysfunction [3].  
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Another therapeutic innovation was the introduction of variceal band ligation (VBL). Several 
comparative trials found VBL to be superior to injection sclerotherapy with regard to the 
complication rate, the number of treatments sessions and time required to achieve variceal 
eradication. Ligation resulted in a corresponding reduction of the variceal rebleeding rate and 
mortality [4].     
The aim of the present study was to compare the efficacy, morbidity and costs of treatment 
with TIPS and VBL in cirrhotic patients with variceal bleeding.  
 
PATIENTS AND METHODS  
 
Patient selection 
Eligible patients were men and women aged 18-75 years with a first or second episode of 
endoscopically proven bleeding from oesophageal varices [5] within two weeks of 
randomisation, who had not been treated previously with TIPS and provided informed 
consent. Patients were excluded for the following reasons: prior episodes with hepatic 
encephalopathy not associated with bleeding, portal vein thrombosis, hepatocellular 
carcinoma or a prognosis that was considered dismal within two weeks for other reasons, 
including terminal liver or multiorgan failure.   
 
Centres, study design, randomisation and informed consent 
This was a multicentre randomised controlled trial that started 1 September 1995. Patients 
were included until 1 September 1997 and followed until 31 December 1998. Participating 
centres were the University Hospital Rotterdam, the Albert Schweitzer Hospital, Dordrecht 
and the St. Franciscus Hospital, Rotterdam.  
Treatment was assigned centrally, by telephone contact or by visiting the trial office, using 
opaque, serially numbered, sealed envelopes prepared by the trial statistician. The sequence 
of treatment allocation was computer generated. Patients were stratified for centre, severity 
of liver disease according to the Child-Pugh classification and previous episodes of variceal 
bleeding. Randomisation followed as soon as possible after a diagnosis of oesophageal 
variceal bleeding was established and criteria for inclusion were fulfilled. The assigned 
treatment was instituted intentionally within 7 days of randomisation. Patients or their next of 
kin provided written informed consent.  
During diagnostic endoscopy band ligation or injection therapy with etoxysclerol or tissue 
adhesives was allowed to stop active bleeding from varices and to prevent rebleeding. All 
patients were treated from the time of admission with a 50 µg bolus injection of octreotide 
followed by intravenous infusion of 50 μg/hour for 48 hours.  
The medical ethical committees of the participating centres approved the study.  
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TIPS  
TIPS implantations were performed according to previously described methods [1, 2]. 
However, in contrast to the policy in most centres, procedures were carried out under 
general anaesthesia. All patients received intravenous antibiotic prophylaxis (1.5 gram 
cefuroxim) 30 minutes before the procedure. No routine anticoagulation was given during the 
procedure or afterwards. Both balloon-expandable (Palmaz stent, Johnson & Johnson) and 
self-expandable (Wallstent, Schneider, Switzerland) metal stents were used. The gradient 
between the portal vein pressure and the inferior vena caval pressure was recorded before 
and after stent insertion. Technical success was defined as a patent stent at the end of the 
procedure and a portal pressure gradient below 12 mmHg. If contrast injection revealed 
persistent significant collateral blood flow additional embolisation using micro coils was 
performed.  
 
Endoscopic band ligation 
Experienced endoscopists performed all endoscopic procedures. Varices were ligated using 
end-viewing endoscopes and a multi-shooter banding device (Speedband®; Boston 
Scientific Corporation, Natick, USA) according to previously described methods [6, 7]. The 
ligation was started at the oesophagogastric junction and extended upwards in a spiral 
fashion, usually until 5-7 cm above the junction. Eradication was defined as disappearance of 
variceal columns or inability to perform further ligation because variceal tissue could no 
longer be ‘sucked’ into the ligation device.  
 
Follow-up treatment 
Care of the patients in both groups was identical and involved clinical and biochemical 
assessment at 1 month and 3-monthly intervals thereafter.   
For the VBL group treatment was repeated at weekly intervals until obliteration, and then at 3 
and 6 monthly intervals. Any persistent or recurrent varices were retreated. When variceal 
eradication had been documented on two successive 6 monthly visits, control examinations 
were scheduled at yearly intervals.  
For the TIPS group shunt function was assessed using Doppler-ultrasonography at 2, 7 and 
30 days after insertion of the shunt and subsequently at 3 monthly intervals. Repeat 
portography and pressure measurements, under local anaesthesia and mild intravenous 
sedation with midazolam, were performed at 1 month and 6 months after TIPS and when 
ultrasonography suggested shunt insufficiency. Shunt insufficiency was treated with balloon 
dilatation or the insertion of additional stents.  
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Definition of key events; management of rebleeding and complications 
We used international consensus definitions for the acute bleeding episode, (significant) 
rebleeding and failure to control bleeding [8]. Rebleeding was defined as the occurrence of 
new haematemesis or melaena after a period of 24 hours or from the 24 hours point of stable 
vital signs and Hct/Hb following an episode of acute bleeding. The acute bleeding episode is 
represented by an interval of 48 hours from time of admission (time zero) with no evidence of 
clinically significant bleeding between 24 and 48 hours. Significant rebleeding was defined as 
a transfusion requirement of 2 units of blood or more within 24 hours of time zero, together 
with a systolic blood pressure < 100 mmHg or a postural change of > 20 mmHg and/or pulse 
rate  >100/minute. Rebleeding was specified in terms of total rebleeding, variceal rebleeding 
and bleeding from other causes. For patients with rebleeding treatment consisted of renewed 
infusion of octreotide during 2 days, urgent (therapeutic) endoscopy and temporarily balloon 
tamponade when indicated. For the TIPS group this was followed by portography, 
measurement of the portal pressure gradient and measures to restore or improve shunt 
function. Treatment failure, and thereby an indication for other therapy, was defined as the 
occurrence of two episodes of recurrent variceal bleeding requiring transfusion of 2 units of 
red blood cells per episode, or the occurrence of three episodes of recurrent variceal 
bleeding and transfusion of 2 units of red blood cells on at least one occasion. When TIPS 
creation was unsuccessful patients were further managed by VBL. When VBL failed the 
choice with respect to further treatment was left to the team taking care for the patient; TIPS 
or a surgical shunt were proposed as the main treatment options in that situation. Shunt 
insufficiency, or dysfunction, was defined as a hepatic portal venous pressure gradient over 
12 mmHg or angiographic documentation of shunt stenosis or occlusion. Hepatic 
encephalopathy was assessed by clinical criteria [9]. All episodes were taken into account, 
irrespective of the presence of possible precipitating factors. Both groups received lactulose 
to prevent hepatic encephalopathy. The standard dose was 30 ml twice daily and was 
adjusted to produce two soft stools daily. Hepatic encephalopathy in both groups was treated 
with increased doses of lactulose and /or temporarily lactulose enemas, and correction of 
potentially precipitating factors including infections, electrolyte disorders and use of 
sedatives. If necessary, dietary protein was restricted and additional treatment with 
antibiotics was instituted.  
 
Analysis of costs  
We performed an analysis of the direct medical costs i.e. costs of the time spent in the 
intensive care unit and on the ordinary ward, and those associated with radiological and 
endoscopic procedures and administration of blood products. Only patients admitted to the 
University hospital Rotterdam were included. Indirect costs, e.g. economic loss related to 
inability to work, were not taken into consideration. Because of the limited number of patients 
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in this study and the high costs associated with (evaluation for and performance of) liver 
transplantation, candidate patients for this procedure were excluded from analysis. The 
mean cumulative costs per patient for both treatment groups were compared.  
 
Statistics 
A sample size calculation was performed assuming 20% and 55% rebleeding rates at one 
year after TIPS and VBL.  To detect this difference with a significance threshold alpha of 0.05 
and a power of 80%, and using the two-tailed test Fisher exact test, we calculated that we 
needed to recruit 35 patients in each treatment group within a period of 2 years. Analyses 
were performed on an intention to treat basis. The primary end-points in this study were 
variceal rebleeding and hepatic encephalopathy. Secondary end-points were complications 
and health-care costs.  
Rebleeding and mortality were analysed using the Kaplan-Meier method. Differences 
between groups were compared with the log-rank test. The Chi-2 test was used to analyse 
differences between groups for qualitative data and paired and unpaired t-tests or their non-
parametric equivalents, where appropriate, for quantitative data.  A p-value < 0.05 was 
considered significant.  
 
RESULTS 
 
Entry of patients into the study was much lower than expected. After 2 years, 37 patients 
were enrolled into the study and it was decided to stop recruitment. Nineteen patients were 
randomised to TIPS and 18 to VBL (figure 1). We excluded 51 patients for the following 
reasons: variceal bleeding more than 2 weeks before randomisation (n = 8), refusal (n = 6), 
hepatocellular carcinoma (n = 7), terminal liver failure (n = 11), performance of emergency 
TIPS for uncontrolled bleeding before randomisation (n = 4), portal vein thrombosis (n = 6), 
death before randomisation (n = 2) and other reasons (n = 7) including inability for follow-up 
or more than two previous variceal bleeding episodes. Patient characteristics were 
comparable for both groups (table 1). Mean follow-up for the total group was 20.9 months 
(range 0.6 - 40); for the shunt group 18.4  12 months and for the VBL group 23.5  11 
months. Mean time from initial diagnostic endoscopy to TIPS was 11.5  6 days and to VBL 
8.7  7 days. Mean time from randomisation to TIPS was 5.7  5 days and to VBL 3.9  3 
days (p=0.2).  
The number of therapeutic endoscopic procedures in the time between admission and 
institution of the allocated treatment was comparable for both groups. In the TIPS and VBL 
group 5 and 3 patients, respectively, had not been treated endoscopically before the 
allocated treatment was instituted while 11 and 13 patients from the respective groups had 
one endoscopic treatment.  The remaining patients had three or four endoscopic treatments.  
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Procedures: TIPS implantation failed in one case due to inability to puncture the portal vein 
and in another case only succeeded at a second attempt. The latter patient developed 
subtotal portal vein thrombosis and, despite anticoagulation, subsequent complete 
thrombosis. Both patients were managed by VBL. During the initial TIPS procedure, coil 
embolisation of portosystemic collaterals was performed in 8 patients. Following TIPS 
insertion, embolisation was performed after 3 and 6 days in 2 other patients undergoing 
portography for shunt insufficiency.  
All patients in the VBL group received this therapy and none of them required TIPS or 
another therapy for uncontrolled variceal bleeding later on. In the VBL group eradication of 
varices was achieved in 14/18 patients after a mean interval of 6 months. Four of these 
patients rebled from recurrent varices on further follow-up. Despite repeated ligation 
treatment complete eradication was not achieved in 4 cases.  
During the trial 1 patient in the TIPS group and 2 in the VBL group received a liver transplant.  
Rebleeding: (Table 2) Rebleeding was observed in 1 patient assigned to TIPS. This was in 
the single patient in whom placement failed and who subsequently was managed by VBL. 
The incidence of rebleeding from varices (figure 2) for the TIPS and VBL groups was 7% and 
32% at 1 year and 7% and 40% at 2 years, respectively (p = 0.03). The incidence of 
significant variceal rebleeding after 1 and 2 years was 7% for the TIPS group and 12% for 
the VBL group (NS).  (When the 2 patients in whom TIPS placement was unsuccessful were 
analysed as being randomised to VBL, the difference remained non-significant).  
Mortality: Nine patients (47%) patients died in the TIPS group and 4 patients (22%) in the 
VBL group. There were no deaths attributable to variceal bleeding (table 3). The 1-year 
survival rate was 68% in the TIPS group and 76% in the VBL group; the 2-year survival rate 
was 61% and 76%, respectively (figure 3). These differences were not significant. Analysis of 
subgroups with Child-Pugh classes A, B or C showed no significant differences.  
Encephalopathy: At the time of randomisation hepatic encephalopathy was diagnosed in 6 
patients. One patient in the TIPS group had grade grade I encephalopathy, improved with 
therapy and had no recurrence after TIPS. In 5 cases assigned to VBL with grade I (n=3), II 
(n=1) and III (n=1) encephalopathy, symptoms responded to treatment but recurred in 3.  
Encephalopathy was a chronic recurrent problem in the 2 patients with grade II/III.  Following 
TIPS de novo encephalopathy developed in 9 (50%) patients, mainly during the first three 
months. In the VBL group encephalopathy was observed in 4 patients. Two patients in the 
TIPS group and 3 in the VBL group required rehospitalization for encephalopathy. The 1 and 
2 year incidence of encephalopathy was 43% and 55% following TIPS and 23%/23% for the 
VBL group (p = 0.13, log-rank test) (figure 4). One patient treated with TIPS and 2 treated 
with VBL had recurrent episodes of encephalopathy; these were Child-Pugh class C patients 
who died of liver failure during follow-up.  
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Complications: In the TIPS group three treatment related complications were observed: 
transient haemolytic anaemia, portal vein thrombosis and fatal haemorrhagic stroke in a 73-
year old female, occurring immediately after portography and introduction of a second stent 
for shunt insufficiency. In the VBL group 3 patients had complications: bleeding from therapy 
related oesophageal ulcers in 2 and gastric perforation after band ligation of the cardiac 
region in one. The latter patient required laparotomy, with a subsequent favourable course.  
Shunt surveillance and function: Two patients did not undergo surveillance portography 
due to early death. Repeat portography was performed on 24 occasions in 15 of the 17 
patients who had successfully inserted shunts. Twelve of these 17 patients (71%) developed 
shunt insufficiency, with complete occlusion in 4 and shunt stenosis in 8. Eight balloon 
angioplasties were undertaken in 8 patients on 10 occasions; in 7 patients additional coaxial 
stents were inserted. Both balloon angioplasty and additional stent insertion for shunt 
insufficiency were performed in 3 cases. Shunt insufficiency was not accompanied by 
rebleeding in any of our patients.  
Costs: During the first month, the mean costs per patient in the TIPS group were € 10909 
and for the VBL group €6818. This difference was caused by higher costs for procedures in 
the TIPS group (€6657) as compared to the VBL group (€2524). The costs of in-hospital 
treatment for both groups were comparable. After two years, the mean cumulative costs per 
patient in the TIPS and VBL groups were €21818 and €15909, respectively. Thus, the initial 
difference between both groups became more marked over time and was not reduced by 
potentially decreased medical consumption of TIPS treated patients because they suffered 
less rebleeding or required less rehospitalization.       
 
DISCUSSION 
 
The results of this randomised trial suggest that TIPS is more effective in preventing variceal 
rebleeding in patients with liver cirrhosis and a first or second episode of haemorrhage from 
oesophageal varices compared to VBL. We were unable to demonstrate an advantage of 
TIPS over VBL with respect to variceal rebleeding defined as significant. Our findings further 
suggest that the lower incidence of rebleeding obtained with TIPS does not translate into a 
survival benefit.  Finally, TIPS seemed to increase the risk for hepatic encephalopathy.    
The obvious major weakness of the present study is its low power, due to our inability 
to enter more patients into the trial. Thus, this trial may easily have failed to detect real 
treatment effects (type II error), but may also suggest treatment effects that are non-existent 
(type I error). Therefore, all results should be interpreted cautiously and clearly this trial does 
not allow drawing conclusions as to the superiority of one treatment modality over the other. 
Nevertheless, we consider it important to report our findings in order to add to the available 
literature data on therapeutic options in variceal bleeding. Particularly, the data reported here 
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may be used in meta-analyses and thereby increase the reliability of the results of such 
studies.   
In this study, TIPS provided full protection against renewed haemorrhage from 
varices in those patients who had technically successfully created shunts and remained free 
from early occlusion due to thrombosis. This applied to 89% of patients intentionally treated 
with TIPS. Surprisingly, although shunt insufficiency developing over time was not 
uncommon, in this small series this was not associated with variceal rebleeding, an 
observation similar to that of Jalan et al. [10]. In contrast, considering the observed 40% risk 
of rebleeding within two years following VBL, this study confirms that VBL is a relative 
ineffective procedure in the secondary prophylaxis of variceal haemorrhage. A therapeutic 
strategy aimed at increasing the efficacy of endoscopic therapy by additional treatment with 
β-blockers was not shown to lead to improved results in recent studies [11, 12].  
The superiority of TIPS in the prevention of variceal rebleeding as compared to 
endoscopic therapy has now been demonstrated in a number of randomised trials [10-17] 
and confirmed by meta-analyses [18, 19]. There are no apparent differences in the outcomes 
regarding the use of sclerotherapy or band ligation [10, 17]. The available data indicate that 
TIPS creation results in a parallel reduction in the mortality rate due to rebleeding. This result 
was not statistically significant in a recent meta-analysis comprising the data of 6 trials 
published as full reports [19]. Re-analysis of these data combined with those of two recently 
fully reported trials [16, 17] and the present trial shows that 9/326 (3%) of patients died of 
variceal rebleeding after TIPS and 30/328 (9%) of patients treated endoscopically, a 
statistically significant difference (Mantel – Haenszel method: p=0.01; Odds ratio 3.4; 95% CI 
1.6-7.4; test for homogeneity p=0.02). This difference may be an underestimation of the 
advantage of TIPS because treatment crossover to ‘salvage’ TIPS was reported for almost 
20% of patients randomised to endoscopic therapy in the case of treatment failure.  
Mortality was not an end-point in this study. No differences between the TIPS and 
VBL groups were established, a finding in accordance with most studies. Analysis of total 
mortality, as reported in 10 trials [10-17] [20] including the present trial, shows that 97/350 
shunted patients died versus 85/353 patients treated endoscopically (p= 0.3; Odds ratio 0.8; 
95% CI 0.6-1.2; test for homogeneity p=0.7). Several factors may explain why TIPS, despite 
being more effective in terms of prevention of (mortality due to) rebleeding, fails to improve 
overall survival. As already discussed, in most studies patients assigned to endoscopic 
therapy were allowed to crossover to shunt implantation when they failed therapy. This may 
have obscured a treatment benefit of TIPS. Also, TIPS may be associated with more (fatal) 
procedure-related complications. In the present study, one death due to stroke seemed 
related to TIPS creation while other fatal complications, including haemoperitoneum [12] [17, 
20] and respiratory depression caused by sedation [10] have been reported. On the whole, 
however, the occurrence of fatal and non-fatal complications seems comparable for 
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radiological shunts and endoscopic therapy. Further, in analogy with surgically constructed 
shunts [21, 22], TIPS may have an adverse effect on liver function, resulting in higher 
mortality from liver failure. However, the combined data of 9 trials [10-13] [15] [20] [16, 17], 
including the present report, indicate that 26/326 (11%) shunted patients died of liver failure, 
compared to 27/328 (8%) endoscopically treated patients, a non-significant difference (Odds 
ratio 0.7; 95% CI 0.4-1.3; test for homogeneity p=0.8). Fatal infectious disease was observed 
more frequently after TIPS (TIPS 4.6% vs. endoscopic therapy 2.7 %), but this difference is 
not significant (Odds ratio 0.6; 95% CI 0.2-1.4; test for homogeneity p=0.8). No clear 
differences between both treatment options are apparent with respect to other causes of 
death. For the time being, it is difficult to find a satisfactory explanation for the unaltered 
mortality risk after TIPS. Possible factors involved are the treatment crossover phenomenon 
and the presence of a type II statistical error.   
Similar to most studies we found that TIPS creation is associated with a higher risk for 
hepatic encephalopathy. Usually this was a transient problem, readily responding to 
appropriate therapy. The serious problem of chronic or recurrent encephalopathy was 
comparable for both treatment groups.  
Data on the relative costs of TIPS and endoscopic therapy are particularly scarce and 
literature data do not allow firm conclusions [18]. Several studies found no difference with 
respect to the rehospitalization rate [17, 20] [16] or costs [14]. However, this has not been a 
uniform finding and both higher [23] and lower [10] costs associated with TIPS have been 
reported. Due to the small sample size, our estimation of costs clearly has a preliminary 
character, but suggests that costs of TIPS implantation are higher than those of endoscopic 
therapy. It remains to be established whether the cost benefit ratio of TIPS may change over 
time, as TIPS may potentially have a beneficial effect on costs related to other complications 
of portal hypertension, such as ascites and ectopic variceal bleeding, while the reintervention 
rate over time may gradually decrease [24]. On the other hand, TIPS could also have an 
opposite effect through a negative effect on liver function.   
In conclusion, TIPS compared with endoscopic therapy is more effective in preventing 
rebleeding from varices. The currently available cumulative data suggest that this results in a 
reduction of bleeding associated mortality. However, TIPS has not been shown to improve 
overall survival. The reasons for this failure await further elucidation. TIPS creation increases 
the risk for hepatic encephalopathy, however this condition usually does not represent a 
major clinical problem. Further studies should concentrate on the question whether TIPS 
may be more effective in particular sub-groups, e.g. patients with pre-existent ascites, gastric 
varices, severe, life-threatening haemorrhage or recurrent haemorrhage despite previous 
endoscopic therapy. It seems attractive to assess these issues in meta-analyses by 
combining individual patient data of the available trials. Also, future studies should evaluate 
whether new types of stents [25, 26] give less rise to shunt insufficiency. If so, TIPS could 
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further decrease the rebleeding rate from varices, with a parallel decrease in the costs of 
surveillance. Despite being relative ineffective in preventing recurrent bleeding from varices, 
and despite other drawbacks such as the necessity of repeated invasive treatment and 
continued surveillance, endoscopic treatment is likely to remain the main treatment option in 
most centres until clearly superior alternatives have been identified.    
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Figure 1 
Trial profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
Kaplan-Meier plot showing the percentage of patients treated with TIPS (n=19) or variceal band 
ligation (n=18) remaining free of rebleeding from oesophageal varices. The difference was statistically 
significant (p=0.03, log-rank test). 
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Figure 3 
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Kaplan-Meier plot showing the estimated survival for patients treated with TIPS (n=19) or variceal 
band ligation (n=18). The difference was statistically not significant.  
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Figure 4 
Kaplan-Meier plot showing the incidence of hepatic encephalopathy for patients treated with TIPS 
(n=19) or variceal band ligation (n=18). The difference was statistically not significant (p=0.13, log-rank 
test).  
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Table 1 
Patient characteristics  
     TIPS   VBL 
Characteristic     n=19   n=18 
Age      50(24-75)  55(23-71) 
Sex (M/F)     12/7   15/3 
Diagnosis (n) 
 Alcoholic liver disease   10   11 
 Cryptogenic cirrhosis   5   1 
 Hepatitis B/C    2   3 
 PBC/PSC    1   2 
 Other     1   1 
Child-Pugh score    7 (5-12)  6(5-11) 
Child-Pugh class A/B/C (n)   9/7/3   9/3/6 
Ascites (n)     9   9 
Infection (n)     0   0 
Encephalopathy (n)    1   5 
First variceal bleeding (n)   12   10 
Gastric varices (n)     8    6                                                                      
Laboratory 
 Bilirubin (μmol/l)   33(11-149)  29.5(12-416) 
 Albumin (g/l)    32(21-45)  33.5(18-43) 
 Prothrombin time (sec. prolonged) 0.95(0-7.7)  0.5(0-5.4) 
 Platelets (x 109/l)    97(36-464)  88(32-374) 
 Creatinine (μmol/l)   67(41-106)  63(38-139) 
 Results are expressed as medians and ranges unless otherwise indicated   
 
Table 2 
Recurrent bleeding 
                                  TIPS   VBL 
                 n = 19    n = 18 
Patients 
Variceal bleeding       1     7 
Significant variceal bleeding     1     3 
Non-variceal bleeding      31     2 
 
Episodes 
Variceal bleeding       1     9 
Significant variceal bleeding     1              4 
1 1 patient did not undergo endoscopy; despite endoscopy cause not established in 2 cases 
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Table 3 
Causes of death 
              TIPS   VBL 
                 n=19    n=18 
 
Liver failure         4   2 
Stroke         3 
Infection1        1 
Pulmonary fibrosis             1 
Myocardial infarction               1 
Oesophageal cancer          1    
  Total        9   4 
 
1 infected total hip arthroplasty  
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ABSTRACT 
 
Background & Aims. TIPS is used to treat complications of portal hypertension. In this study 
the clinical results for 82 patients were evaluated. 
Methods. Patients were followed for at least 3 years. 54 patients underwent TIPS for variceal 
bleeding, 24 for refractory ascites and 4 for other indications. 
Results. TIPS placement was successful in 92%. Mean follow-up was 29.4 months. Primary 
patency was 22% and 12%, primary-assisted patency 67% and 46%, and secondary patency 
91% and 91% at 1 and 5 years, respectively. Non-alcoholic etiology and increasing platelet 
counts independently predicted the development of shunt insufficiency. One and five year 
rate of recurrent variceal bleeding was 21% and 27%. The majority of surviving patients 
showed a response of ascites. The risk for encephalopathy of any degree was 25% at 1 
month and 52% at 3 years. The risk for chronic or severe intermittent encephalopathy was 
15% and 20% at 1 and 3 years, respectively, and age and baseline serum creatinine were 
independent risk factors. Overall survival was 61%, 49% and 42% at 1, 3 and 5 years, 
respectively. Age, serum albumin and creatinine were independently related to mortality. 
Conclusions. The risk for definitive loss of shunt function was 17% at 5 years, indicating that 
surveillance with shunt revision when indicated results in excellent long-term TIPS patency. 
TIPS effectively protects against recurrent bleeding. The role of TIPS in the management of 
patients with refractory ascites is limited. 
 
INTRODUCTION 
 
During the past decade the transjugular intrahepatic portosystemic shunt (TIPS) was used 
increasingly for the treatment of complications of portal hypertension. The clinical 
effectiveness of this approach has been documented extensively (1). The duration of follow-
up in most studies, however, was relatively short, with reported (mean/median) follow-up 
times rarely exceeding 2 years (2, 3).  
Since TIPS was introduced into clinical practice in 1988 (4) it was recognized that the 
development of shunt dysfunction due to thrombosis or intimal hyperplasia forms the 
Achilles’ heel of the procedure. Therefore, the role of TIPS in the long-term management of 
complications of portal hypertension has been questioned (5, 6). However, with regular 
follow-up and re-intervention when indicated, excellent 2-year patency rates of up to 90% 
have been reported (7-10), but the follow-up time in studies that produced Kaplan-Meier 
estimates of (primary, primary-assisted and secondary) shunt patency did not exceed 18 
months (7-16). Therefore, long-term patency of TIPS is not well defined and it is not clear 
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whether the development of shunt dysfunction is a chronic, relentless problem or that its 
incidence decreases over time.  
The aim of the present study was to assess the outcome of TIPS in a non-selected group of 
consecutive patients who were followed for at least three years according to a standard 
protocol that included repeated shunt evaluations. In particular, we assessed the pattern of 
(definitive) shunt loss over time and tried to identify clinical variables that predict the 
development of shunt insufficiency.  
 
MATERIALS AND METHODS 
Study population  
From January 1992 until January 1998 TIPS placement was attempted in 82 patients. Patient 
characteristics are presented in table 1. The cohort of 75 patients for whom the procedure 
was technically successful was followed for a period of at least 3 years. Data were recorded 
until January 2001. 
 
TIPS procedure 
The method of TIPS insertion has been described in detail elsewhere (17) and is only 
summarized here. Procedures were performed under general anesthesia. All patients 
received intravenous antibiotic prophylaxis (1.5 grams cefuroxime) 30 minutes before the 
procedure. During the first year of TIPS implantation at our center, anticoagulation consisting 
of iv heparin was started during the procedure and continued for 1 week. This policy was 
abandoned after having witnessed fatal gastric variceal bleeding during heparin 
administration in a patient who underwent TIPS for refractory ascites.  
Catheterization of the hepatic vein was performed through the right internal jugular vein. 
Guided by sonography and fluoroscopy, a needle was advanced through the liver 
parenchyma into a branch of the portal vein. A guide-wire was then passed into the portal 
vein and the parenchymatous tract was dilated using an angioplasty catheter. After balloon 
dilatation a balloon expandable (Palmaz stent, Johnson & Johnson) or self-expandable 
(Wallstent, Schneider, Switzerland) stent was introduced. Just before and after stent 
placement, pressures in the portal and caval vein were recorded and the pressure gradient 
was calculated. If necessary, additional balloon dilatation was performed to reduce the 
pressure gradient below 12 mmHg. In patients with variceal bleeding and persistent 
significant variceal perfusion after shunt placement, embolization was usually performed with 
coils.  
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Table 1: Patient characteristics 
Total number of patients 82 
Sex (M/F) 53/29 
Age (median with range) 52 (24-79) 
Etiology of the liver disease (%)  
Viral 15 (18) 
Alcoholic 36 (44) 
Viral and alcoholic 1 (1) 
Cholestatic 5 (6) 
Autoimmune hepatitis 3 (4) 
Budd-Chiari syndrome 3 (4) 
Cryptogenic 13 (16) 
Other* 6 (7) 
Indication for TIPS (%)  
Esophageal variceal bleeding 36 (44) 
Gastric variceal bleeding 13 (16) 
Ectopic variceal bleeding 5 (6) 
Refractory ascites 24 (29) 
Ascites and hydrothorax 2 (2) 
Budd-Chiari syndrome 1 (1) 
Hepatorenal syndrome 1 (1) 
Child-Pugh class (%)  
A 27 (33) 
B 45 (55) 
C 10 (12) 
Median interval bleeding-TIPS in months 
(range)** 
0.3 (0-6.9) 
Median number of prior endoscopic therapy 
sessions (range)** 
3 (0-17) 
Emergency/elective procedure** 13/41 
* Other: hemochromatosis, myelofibrosis, nodular regenerative hyperplasia, 
alpha-1-antitrypsin deficiency 
** For patients treated for variceal bleeding 
 
Follow-up protocol 
Doppler-ultrasonographic assessment of stent function was performed on days 2, 7 and 30, 
at 3-month intervals during the first year and every 6 months thereafter. Angiography was 
performed routinely at 6 months and in the event of suspected stent dysfunction, based on 
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clinical or ultrasonographic findings. Revision of the stent was performed when occlusion or 
stenosis were seen on the angiography, and also when the portocaval pressure gradient was 
elevated despite normal angiographic findings.  
This protocol was modified in January 1997. From then on patients were subjected to routine 
catheterization at 1 and 6 months. This change was made in an attempt to reduce the 
number of patients with shunt dysfunction at 6 months. 
Clinical, laboratory and other relevant data were recorded on day 7, at 1 and 3 months and 
subsequently at 6-month intervals.  
Follow-up continued until January 2001, death or liver transplantation. Data for patients lost 
to follow-up or undergoing orthotopic liver transplantation were censored at the time of the 
last visit or at the time of transplantation.  
 
Definitions 
Primary patency was defined as patency of the stent without any reintervention. Primary-
assisted patency was defined as a patent stent after reintervention, but without occlusion at 
any time. Secondary patency was defined as a patent stent after occlusion, which ends at 
the moment an untreated or untreatable occlusion is present (7). Shunt occlusion was 
defined as the absence of flow on ultrasonography or angiography. 
Complications were defined as clinical events observed within 30 days of the TIPS 
procedure, which were certainly or possibly related to the procedure and required adjustment 
of medical management (e.g. prolongation of stay in intensive care unit or hospital, institution 
of antibiotic treatment). Short- and long-term complications were defined as complications 
occurring within 1 week of the procedure and after the first week, respectively. These 
complications did not include hepatic encephalopathy and shunt dysfunction, since these 
were recorded and analyzed separately. Variceal bleeding and rebleeding were defined 
according to internationally accepted criteria (18, 19). Only patients who underwent the TIPS 
procedure for variceal bleeding were analyzed for rebleeding. 
The effect on ascites was assessed using criteria suggested by Rossle et al. (2). A complete 
response was defined as elimination of ascites, a partial response as persisting ascites but 
not requiring paracentesis and absence of response as ascites requiring paracentesis. Only 
patients who received a TIPS for refractory ascites were assessed for the effect on ascites. 
Hepatic encephalopathy was assessed according to Opolon (20) as follows: grade I: 
lethargy, reversal of day-night sleep pattern, normal orientation, no flapping tremor; grade II: 
slurred speech, somnolence, inadequate behavior, difficult handwriting, flapping tremor; 
grade III: disorientation in time, place or person, pre-coma; grade IV: coma. Chronic 
encephalopathy was defined as clinical encephalopathy which did not respond to medical 
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treatment and a protein-restricted diet. Severe intermittent encephalopathy was defined as 
disabling intermittent encephalopathy despite treatment. 
 
Statistical analysis 
Data processing and analysis were performed using SPSS version 9. Student’s t-test was 
used to analyze differences between groups. Encephalopathy, shunt patency, survival and 
rebleeding curves were created according to Kaplan and Meier and compared by means of 
the log-rank test. Cox regression analysis was performed to assess factors related to 
encephalopathy, shunt patency and mortality. Logarithmic transformations (base 10) of 
serum creatinine levels and platelet counts were used. The Cox proportional hazards model 
was applied to assess factors independently related to encephalopathy, patency and 
mortality. We included those factors found to be significant or showing a trend (p< 0.1) in the 
univariate analysis. Non-significant factors in the multivariate analysis were subsequently 
removed until factors with independent prognostic significance remained. A two-tailed p-
value ≤ 0.05 was considered significant.  
 
RESULTS 
 
Creation of a functional stent was achieved in 75 of the 82 patients (91%).  
Three of the seven unsuccessful procedures occurred within the first year of introduction of 
the technique. Reasons for failure were: unsuccessful puncture of the portal venous system 
(n=5), intraperitoneal bleeding due to perforation of the extra hepatic portal vein (n=1) and 
stent occlusion during placement (n=1). The mean duration of follow-up was 29.4 ± 29.5 
(range 0.3 – 105.5) months. Patients (n=22) who were still in the study at the end of the 
follow-up period had been followed for a mean of 60.1 ± 21.5 months. Two patients were lost 
to follow up at 1 and 32 months. Six patients underwent liver transplantation after 1, 2, 3, 12, 
27 and 74 months, respectively. 
 
Complications 
Short-term complications occurred in 16 patients (Table 2). They proved to be fatal in three 
cases: one patient died from heart failure, one from sepsis and one from intraperitoneal 
bleeding. A long-term complication, sepsis occurring 15 days after TIPS placement, was 
observed in one case. Another potential complication was pulmonary hypertension, observed 
in one case after 14 months (21).  
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Table 2: Short-term complications 
Complication (no. of patients) 
Sepsis (3) 
Intraperitoneal bleeding (3) 
Aspiration pneumonia (2) 
Jugular vein hematoma (2) 
Thrombocytopenia (1) 
Hemolysis (1) 
Hemobilia (1) 
Liver capsule perforation (1) 
Hematothorax (1) 
Heart failure (1) 
Bleeding of arterial line (1) 
 
Shunt patency 
The portocaval pressure gradient decreased from a mean of 15 mmHg before the TIPS 
procedure to a mean of 7.3 mmHg after successful placement of the TIPS (p<0.0001).  
The median number of TIPS recatheterizations was 1 (range 0-6); the median number per 
patient follow-up year was 0.5. Patency curves are shown in figure 1. The primary patency 
rate was 22% at 1 year, 17% at 2 years and 12% at 4 and 5 years. The primary-assisted 
patency rate was 67% at 1 year, 62% at 2 years, 51% at 4 years and 46% at 5 years. The 
secondary patency rate was 91% at 1 year, 86% at 2 years, and 83% at 4 and 5 years.  
The following factors were included in univariate Cox regression analyses of primary, 
primary-assisted and secondary TIPS patency: age, sex, serum bilirubin, serum creatinine, 
platelet count, Child-score, diabetes mellitus, ascites, alcoholic versus non-alcoholic etiology, 
Wall-stent versus Palmaz stent and portal pressure gradient, portal pressure and caval vein 
pressure before and after TIPS insertion. Platelet count and alcoholic etiology were found to 
be significant predictors of the primary patency in both univariate and multivariate analyses 
(Table 3). Thus, alcoholic etiology and lower platelet count were predictive for the absence of 
shunt failure. No significant predictive factors were found for the primary-assisted or 
secondary patency rate. 
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Fifteen patients (20%) had experienced encephalopathy sometime before receiving TIPS. At 
the time of TIPS placement, 7 (9%) patients had clinical evidence of encephalopathy. In 
three of these cases encephalopathy became a chronic problem while it was transient in the 
others.  
TIPS cohort study 
After introduction of the TIPS, 37 (49%) patients developed a new episode of clinical 
encephalopathy. Grade I encephalopathy occurred in 32%, grade II in 30%, grade III in 14% 
and grade IV in 14% of the patients. In 4 cases the grade of encephalopathy was not 
recorded. Most cases could be managed successfully by correction of the precipitating 
44% at 1 
tivariate analysis 
after TIPS.  
Univariate analysis for chronic or severe intermittent encephalopathy showed that age, 
creatinine and encephalopathy prior to TIPS were predictive factors. In multivariate analysis, 
however, only age and serum creatinine remained as independent predictors for the 
development of chronic or severe intermittent encephalopathy.  
factors and administration of lactulose. Antibiotic treatment and/or a protein-restricted diet 
were instituted when symptoms persisted. Chronic or severe intermittent encephalopathy 
occurred in 12 patients; the median age of this group was 64 years. Nine of these 12 patients 
died due to hepatic failure, 2 due to infections; 1 underwent liver transplantation.  
The risk for encephalopathy of any degree was 25% at 1 month, 40% at 6 months, 
year, 47% at 2 years and 52% at 3 years (Figure 2, A). The risk for chronic or severe 
intermittent encephalopathy was 15%, 18% and 20% at 1, 2 and 3 years, respectively 
(Figure 2, B). There was no significant difference in shunt diameter between patients who did 
and did not develop encephalopathy after receiving a TIPS (8 vs. 9.5 mm, p=0.25). 
The following factors were included in univariate Cox analyses of encephalopathy: age, sex, 
alcoholic versus non-alcoholic etiology, serum bilirubin, serum creatinine, Child-Pugh score, 
ascites, encephalopathy prior to and at the time of TIPS placement, portal pressure gradient 
before and after TIPS insertion and stent diameter. Age, non-alcoholic etiology, 
encephalopathy prior to and encephalopathy at the time of TIPS placement, Child-Pugh 
score and creatinine were all found to be predictors of encephalopathy. Mul
showed that age, non-alcoholic etiology and encephalopathy at the time of TIPS placement 
were the main factors independently related to development of post-TIPS encephalopathy 
(Table 3). Alcoholic etiology, lower age and absence of HE before the TIPS procedure were 
favorable factors regarding the development of encephalopathy 
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Figure 2: Probability of developing hepatic encephalopathy of any degree (a) and chronic or severe 
intermittent hepatic encephalopathy (b) in years for 75 patients who underwent a TIPS procedure 
(inverse Kaplan-Meier plot) 
 
Rebleeding 
Recurrent bleeding from varices and due to non-variceal causes was observed in 10 (21%) 
and 9 (19%) of the 48 patients, respectively, who successfully underwent the TIPS procedure 
for secondary prevention of variceal bleeding. In one case variceal rebleeding occurred after 
48 months; venography showed total occlusion and a new, parallel TIPS was inserted. Nine 
out of ten cases of variceal rebleeding occurred within 6 months (mean 51 days, range 1 - 
173) of TIPS insertion. In two of these cases total shunt obstruction was due to thrombosis 
and intimal hyperplasia, respectively, and TIPS revision was performed. In another two cases 
shunt stenosis, but without total obstruction, was treated with balloon angioplasty. In one 
case of rebleeding 1 day after TIPS insertion, Doppler ultrasonography showed normal TIPS 
function. TIPS catheterization was not performed and the patient underwent endoscopic 
injection therapy. In the remaining four cases of variceal rebleeding, portal venography 
showed no abnormalities and portal-caval vein pressure gradients were below 12 mmHg. 
However, venography showed the presence of patent collaterals, in particular significant 
persistent portal blood flow via the coronary vein in three cases and via the inferior 
mesenteric vein in one case. The latter patient had received a TIPS for recurrent bleeding 
from anorectal varices. Embolization of the collaterals was performed in all four cases.  
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A second episode of recurrent gastro-esophageal variceal bleeding occurred in two cases. In 
one patient balloon dilatation for shunt stenosis had been performed 6 days earlier after a 
first recurrence of hemorrhage; this patient was in a very poor condition and died shortly 
afterwards. In the other patient TIPS function was normal but portal venography showed 
persistent significant collateral blood flow. For technical reasons embolization was 
unsuccessful. During the subsequent 5-year follow-up this patient suffered no recurrences.  
The 1-, 2- and 5-year rates of recurrent bleeding from varices were 21%, 21% and 27%, 
respectively (Figure 3).  
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Figure 3: Kaplan-Meier plot showing the probability of remaining free of rebleeding in years for 48 
patients who underwent a TIPS procedure for variceal bleeding 
 
Ascites 
The TIPS was successfully introduced in all but one case of refractory ascites. Table 4 
summarizes the response to the TIPS at 1, 3, 6, 12 and 36 months. For these 23 patients 
mortality at 6 months was 43%; at 3 years 14/23 patients (61%) had died. Causes of death 
were liver failure (n=7), renal failure (n=2) that was already apparent before the TIPS 
procedure, variceal bleeding (n=2), pneumonia (n=2), and hepatocellular carcinoma (n=1). 
Two patients underwent liver transplantation. Among survivors a complete or partial 
response was observed in the majority of cases. For these patients diuretic therapy was 
reduced significantly. 
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Table 4: Data on clinical course and response to TIPS for 23 patients with refractory ascites 
 Month 
 1 3 6 12 36 
complete response 6 6 3 3 4 
partial response 6 4 6 4 1 
non-response 7 4 2 2 1 
Dead 3 7 10 11 14 
Transplantation 0 1 1 2 2 
lost to follow-up 1 1 1 1 1 
 
Survival 
Two patients died within the first week, one from hepatorenal syndrome and sepsis and one, 
treated for refractory ascites, from massive gastric variceal bleeding while receiving 
intravenous heparin. During follow-up 45/75 (60%) patients died. Causes of death were liver 
failure (n=19; 42%), variceal bleeding (n=4; 9 %) and other causes (n=22; 49%). Survival at 1 
month was 88%, at 6 months 68%, at 1 year 61%, at 3 years 49% and at 5 years 42% 
(Figure 4).  
The following factors were included in univariate Cox regression analyses: sex, age, 
presence of ascites, history of encephalopathy, indication (variceal bleeding vs. other), 
serum creatinine, albumin and bilirubin, platelet count and Child-Pugh score. Age, ascites, 
creatinine, albumin and Child-Pugh score were all found to be significant predictors of 
survival. Multivariate analysis of these factors with backward elimination showed that age, 
serum albumin and serum creatinine were the most important factors independently related 
to mortality (Table 3). 
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Figure 4: Kaplan-Meier plot of survival following TIPS insertion in 75 patients (years). 
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DISCUSSION 
 
The present study confirms that introduction of the TIPS is not a single-step procedure and 
that repeated interventions are required to maintain function in a large majority of the 
patients. However, our data also show that efforts to maintain TIPS function can eventually 
result in good long-term patency and suggest that (definitive) shunt loss 3-4 years after the 
TIPS procedure is rare. We observed a shunt loss of 17% at 5 years. This may not be 
markedly different from the reported figures for surgical shunts, which ranged from 11-20% 
(22-27). Our data are compatible with earlier suggestions that in a subset of patients pseudo-
intimal proliferation may be a self-limiting process (10) and that the necessity for shunt 
revisions may decrease over time (28). 
Up until now no generally accepted guidelines for shunt surveillance have emerged, and 
follow-up protocols differ from center to center (7, 15, 17). Most centers use both 
ultrasonography and venography, but the optimal sequence and time intervals remain to be 
established. In general, ultrasonography is non-invasive, inexpensive and simple but 
compared to angiography, an invasive and expensive procedure, the sensitivity and 
specificity for detecting shunt dysfunction may be less (29). Local experience and expertise 
are likely to be of decisive importance in the choice of the optimum protocol for a given 
center. Recent developments in ultrasonography, such as contrast-enhanced Doppler 
sonography and power Doppler sonography, might increase the value of this technique for 
detecting shunt dysfunction (30, 31).  
When interpreting data on primary and secondary shunt patency, the influence of the type of 
surveillance method should be taken into account. It is conceivable that centers using routine 
angiography are likely to do more (early) reinterventions, resulting in lower primary patency 
rates. Therefore, for the interpretation of the results of individual studies, reported secondary 
patency rates may be more informative. 
Previous studies reported a number of risk factors for developing shunt insufficiency, 
including diabetes mellitus (32), biliary-venous fistulae (9, 33), female sex (32), age over 55-
65 years (32), Child-Pugh score (34), low prothrombin times (17), high platelet counts (17), a 
porto-caval pressure gradient > 18 mmHg prior to the TIPS procedure (35) and portal vein 
pressure (36). We identified non-alcoholic liver disease and platelet count as risk factors for 
developing shunt dysfunction. A role of platelets was not supported by the findings of a 
controlled trial evaluating acetylsalicylic acid for the prevention of shunt occlusion (37). In 
contrast, a significant reduction in the incidence of shunt stenosis was reportedly achieved by 
combined treatment with ticlopidine, a platelet aggregator inhibitor, and trapidil, a drug with 
anti-platelet-derived growth factor activity (38). (Moderate) consumption of alcohol, 
particularly red wine, has been reported to decrease the risk for peripheral (39), 
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cardiovascular and cerebrovascular arterial disease (40, 41). Alcohol may also decrease the 
risk for venous thromboembolic events (42). One mechanism by which alcohol could have an 
effect on vascular disease is through inhibition of platelet reactivity (43). Clearly, findings on 
risk factors for developing TIPS insufficiency have been far from consistent. Both this study 
and other studies suggest that the absolute number of platelets (17) as well as platelet 
function (38) may be implicated. Further studies are needed to address the potential role of 
platelets and the medical modulation of platelet involvement. In addition, technical 
innovations such as the introduction of less thrombogenic, covered or drug-eluting stents are 
important in attempting to find a solution for the critical problem of shunt obstruction (44-46). 
Hepatic encephalopathy is an inherent problem of portosystemic shunting. Reported risk 
factors are age (17, 47-49), bleeding (50) and encephalopathy prior to the TIPS procedure 
(34, 35, 48), Child-Pugh score (34), non-alcoholic etiology (50, 51), female sex (51), 
hypoalbuminemia (51) and a portocaval pressure gradient < 10 mmHg after TIPS placement 
(49). In the present study, risk factors for the occurrence of encephalopathy after the TIPS 
procedure were encephalopathy prior to the introduction of the TIPS, increasing age and 
non-alcoholic etiology of the underlying liver disease. Age and encephalopathy prior to TIPS 
are well recognized factors, but the lower risk for encephalopathy in alcoholic cirrhosis, that 
was also found by others (51), is difficult to explain, considering that shunt patency in 
alcoholic patients was better and the incidence of subclinical encephalopathy in these 
patients may be higher (52). In approximately one-third of the patients with encephalopathy 
after a TIPS procedure, it was chronic or present intermittently. Independent risk factors were 
increasing creatinine and age over 65 years. In patients over 65 years and those with 
elevated creatinine levels the indication for TIPS should be considered very carefully and 
extra care should be taken to prevent, detect and treat encephalopathy. 
Our results for patients receiving a TIPS for refractory ascites are in agreement with 
previously reported data (53-58) and show that in a number of cases the TIPS may provide 
long-term control of previously refractory ascites. However, the general prognosis for patients 
with refractory ascites is grave, with reported one-year survival rates after the TIPS 
procedure not exceeding 30-50 percent (53-55, 57). This underlines the fact that liver 
transplantation should always be the primary therapeutic approach for this patient group. 
Two of our patients received a TIPS while having long-standing organic (non-hepatorenal) 
kidney disease with renal insufficiency. The TIPS was ineffective and both patients died 
within 4 months. This experience is comparable to that reported by others (54, 55, 58) and 
confirms that for patients with chronic renal insufficiency, e.g. with a serum creatinine level of 
more than 200 μmol/l, a TIPS is not suitable as treatment for refractory ascites. Two studies 
(2, 57) have compared the TIPS with large-volume paracentesis, a procedure that is often 
regarded as the treatment of choice for refractory ascites. The TIPS was found to have a 
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beneficial effect on ascites; this was associated with an improvement in transplantation-free 
survival but not with an increased risk for encephalopathy in the largest trial (2). Currently 
available data indicate that the TIPS is a reasonable therapeutic option for patients with 
refractory ascites. Patients over 60-65 years of age and those with chronic renal impairment 
are unlikely to benefit from a TIPS; repeated paracentesis seems to be a better alternative in 
such cases.  
In conclusion, after a TIPS procedure, regular surveillance with shunt revision when indicated 
can eventually result in excellent long-term patency. In our study the risk for definitive shunt 
loss was 17% at 5 years. The TIPS effectively protects against rebleeding in the majority of 
patients with variceal bleeding. Recurrent variceal hemorrhage is usually due to shunt 
insufficiency but persistent significant perfusion of portosystemic collaterals is another 
important cause. Severe encephalopathy can be expected to occur, particularly in patients 
over 65 years of age and in those with renal impairment.  
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Chapter 8 
SUMMARY 
 
Objectives: to assess the results of a therapeutic strategy for initial local therapy followed by 
a shunting procedure, if indicated, for patients with portal hypertension and bleeding ectopic 
varices. To report our experience over an eighteen-year period with this uncommon 
condition.  
Design: cohort study 
Setting: University hospital; referral centre for liver diseases  
Participants: 22 consecutive patients with bleeding from colorectal, duodenal, jejuno-ileal, 
stomal, intraperitoneal and cutaneous varices 
Main outcome measures: recurrence of bleeding 
Results: Diagnosis and appropriate treatment were frequently delayed, particularly  in cases 
of intraperitoneal, jejuno-ileal and rectal variceal bleeding. The probability of renewed 
bleeding after local therapeutic procedures (n=19) was 61% at 1 month and 80% at 6 
months. After introduction of second-line therapy (shunting procedures) recurrence occurred 
in 18% at 6 months and 27% after 1 and 5 years. Two patient treated primarily with a surgical 
shunt did not suffer a recurrence.  
Conclusion: For patients with portal hypertension and bleeding not explained by gastro-
oesophageal varices, the possibility of ectopic variceal bleeding should always be 
considered. Local therapies frequently fail. Shunt procedures seem to be the best therapeutic 
approach and may be required in the majority of patients. However, shunt procedures may 
not always be possible and other therapies may occasionally also provide long-term control 
of bleeding.  
 
INTRODUCTION 
 
Ectopic varices can be defined as varices occurring anywhere except in the cardio- 
oesophageal region, the preferred site for the development of portosystemic collateral veins 
in patients with portal hypertension. Bleeding from these varices, which has been observed 
throughout the gastrointestinal tract but also in the genitourinary and biliary tracts, the 
abdominal wall, the peritoneal cavity, the skin and the lung (1-3), has been estimated to 
account for between 1% and 3% of all variceal haemorrhages (1). Literature on this subject 
consists mainly of case reports and small series, the largest consisting of 17 cases of 
bleeding from stomal varices (4). The rarity of the condition and the absence of controlled 
trials of therapeutic modalities explain why the long-term course and optimal management 
are poorly defined. This report describes experience in a single institution with ectopic 
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variceal bleeding over an eighteen-year period, focussing on the therapeutic results of a two-
step therapeutic strategy.   
 
PATIENTS AND METHODS 
 
This series includes all consecutive patients diagnosed with bleeding from ectopic varices 
between January 1984 and December 2001. During this period our therapeutic strategy 
consisted of an initial local, non-shunting procedure, aimed at obtaining haemostasis and 
prevention of renewed bleeding, followed by a surgical or transjugular intrahepatic 
portosystemic shunt (TIPS), if the initial approach failed. TIPS was the preferred shunting 
method after this procedure was introduced in our hospital in 1991. For patients with 
intraperitoneal variceal bleeding, local procedures were considered inappropriate (1) and 
therefore a shunt procedure was the therapy of first-choice. Local therapies included 
(endoscopic) injections of either 2% etoxysclerol or bovine thrombin or combinations of these 
agents, endoscopic band ligation, surgical ligations, reinsertion of enterostoma, subtotal 
colectomy and segmental small-bowel resection.  
At the time of diagnosis patient data were recorded; subsequently the database was updated 
on a yearly basis with respect to clinical course and therapies. Follow-up ended on 1 
December 2001.  Patients lost to follow-up were censored at the time of the last consultation. 
For patients receiving a liver transplant follow-up ended at the date of surgery.  Recurrent 
bleeding and mortality were analysed using the Kaplan-Meier method.  
 
RESULTS 
 
During the study period 22 patients were diagnosed with ectopic variceal bleeding (table 1). 
The total number of new cases of variceal bleeding was about 540, resulting in an estimated 
4% prevalence of bleeding from ectopic sites. The mean duration of follow-up was 48 ± SD 
58 months (range 3 days – 18 years). Two patients were lost to follow-up after 12 months.  
Diagnostic aspects 
In seven of eight patients with colorectal varices, bleeding was a recurrent problem that had 
required repeated hospital admissions and blood transfusions. In all, blood loss was initially 
attributed to haemorrhoids and haemorrhoid surgery had been performed previously in six 
cases without success. In four cases, varices were associated with anal prolapse. The 
diagnosis was based on endoscopic and visual inspection (5); additional endorectal 
ultrasound, technetium erythrocyte scanning and angiography was performed each in one 
case. In our experience, stomal varices were usually not clearly visible on (endoscopic) 
inspection. Submucosal collaterals were visualised by means of ultrasound examination 
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while active and, occasionally spurting, bleeding from tiny red mucosal spots was observed 
on at least one occasion in each case. The diagnosis for patients with duodenal varices was 
made endoscopically while cutaneous variceal bleeding was diagnosed by observing actual 
bleeding from, ultrasound-verified, cutaneous collaterals. Intraperitoneal variceal bleeding 
was diagnosed when free intrabdominal blood was found in the presence of peritoneal 
collaterals in the absence of other potential causes during laparotomy. In one case of a man 
who suddenly succumbed at home this was a post-mortem diagnosis. In another case this 
diagnosis was only considered seven weeks after a first intraperitoneal haemorrhage and 
one week after a second episode and a ‘negative’ exploratory laparotomy. In our three cases 
of ileal and jejunal variceal bleeding the possibility of the diagnosis was not even considered 
for several weeks. Diagnosis was based on the exclusion of other potential causes of 
bleeding and confirmed by radioactive red cell scanning showing blood accumulation within 
the small bowel and findings during laparotomy, including peroperative enteroscopy.  
Nine of our 22 patients - four with stomal, three with jejuno-ileal and two with cutaneous 
varices - had undergone previous abdominal surgery, that had induced and could explain the 
development of varices either at the site of an enterostomy or adhesions (1).  
 
Initial treatment 
Two patients diagnosed with intraperitoneal variceal bleeding received a surgical portocaval 
shunt after 7 days and 10 weeks, respectively, while bleeding in another case was fatal.  In 
all other nineteen patients a local therapy was instituted. Six of the eight patients with rectal 
variceal bleeding were treated initially with injection sclerotherapy (etoxysclerol 2%, in two 
combined with bovine thrombin) or band ligation (n=1); in one patient varices were treated 
with surgical sutures and another patient underwent emergency subtotal colectomy for 
massive bleeding from varices associated with portal venous thrombosis. Three of the four 
patients with stomal varices were treated with injection sclerotherapy and in one case the 
stoma was reinserted. The two patients with duodenal variceal bleeding and one patient with 
cutaneous variceal bleeding received injection sclerotherapy; in one patient with cutaneous 
variceal bleeding local treatment consisted of surgical sutures. In the three cases of jejuno-
ileal variceal bleeding segmental small-bowel resection was performed. In the latter condition 
the a priori preferred therapy was a shunt procedure; however, this proved impossible due to 
either extensive thrombosis of the portal venous system (n=2) and/or a poor clinical condition 
(n=2).  
 
Recurrent bleeding 
After local treatment, bleeding did not recur in 5/19 patients: one case each of duodenal 
(injection sclerotherapy), rectal (band ligation) and cutaneous varices (injection 
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sclerotherapy) and two cases of ileal varices (segmental small-bowel resection) during a 
mean follow-up of 41.5 months (range 0.2 - 123). In 14 /19 (74%) cases of colorectal, small-
bowel, stomal and cutaneous varices recurrent bleeding after local treatment was observed. 
The probability of renewed haemorrhaging after 1, 2 and 6 months was 61%, 75% and 80%, 
respectively (figure 1). Second line therapy - TIPS in seven cases, a surgical shunt in three 
and restoration of the continuity of the bowel in a patient with enterostomal varices - was 
instituted after 0.5 - 18.5 (mean 4.2) months, after 1-4 (mean 3) recurrent haemorrhages and 
administration of 0 - 31 (mean 7.5) units of packed red blood cells; at that time local 
treatment had been repeated in ten cases (eight underwent 2 local procedures, two 3 
procedures). Two patients with rectal varices had not received blood transfusions before a 
TIPS procedure was carried out. They had suffered multiple bleedings resulting in chronic 
anaemia and had invalidating mechanical complaints associated with large anorectal varices. 
Despite recurrent bleeding second-line therapy was not introduced in three cases because 
blood loss was minor (n=1) or shunting procedures were not possible (n=2). After 
introduction of second-line therapy mild anorectal bleeding and discomfort in the presence of 
anal prolapse persisted, following TIPS, in three patients. In one of these cases additional 
embolization of the inferior mesenteric vein was performed. The probability that renewed 
bleeding will not occur after second-line therapy was 82% after 0.5 years and 73% after 1 
and 5 years (figure 1). 
Two patients diagnosed with intraperitoneal variceal bleeding remained free of recurrent 
bleeding after portocaval shunt surgery during 3.3 and 7 years of follow-up. 
 
Mortality 
The 1, 2 and 5 year survival rates were 73%, 57% and 41%, respectively. Thirteen patients 
died, one from massive intraperitoneal variceal bleeding. Other causes of death included 
liver failure (n=5), gastric variceal bleeding, hepatocellular carcinoma, colon cancer, lung 
cancer, stroke and myelofibrosis. In one case the cause remained unknown.    
 
Patients with  non-cirrhotic portal hypertension 
Non-cirrhotic portal hypertension was diagnosed in 6 patients. Three patients with portal vein 
thrombosis were observed with bleeding from duodenal, rectal and ileal varices in one case 
each. No recurrence of bleeding occurred in those patients with duodenal and ileal varices 
after local therapies, injection sclerotherapy and ileal segment resection, respectively. The 
patient with rectal varices underwent subtotal colectomy after massive bleeding. Due to 
extensive thrombosis of the portal venous system decompressive surgery was not possible. 
He continues to have chronic blood loss from ileo-rectal varices and requires intravenous 
iron therapy.   
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Three patients had non-cirrhotic portal hypertension due to myelofibrosis, nodular 
regenerative hyperplasia and idiopathic portal hypertension. The patient with the latter 
condition was confirmed to bleed from ileal varices during laparotomy and underwent local 
segmental resection. This patient with a history of diabetes mellitus, wide-spread 
atherosclerotic vascular disease, myocardial infarction, bronchial carcinoma and gastric 
lymphoma was in a particular poor condition and a shunt procedure was not considered 
feasible; he died 6 weeks after surgery without having had recurrent bleeding. The other two 
patients had rectal variceal bleeding that recurred on several occasions after injection 
sclerotherapy. After TIPS, mild intermittent blood loss persisted; in one case additional 
embolization of the inferior mesenteric vein was performed.  
 
DISCUSSION 
 
Our study indicates that local therapies frequently fail to provide long-term control of bleeding 
from ectopic varices and suggests that procedures aimed at lowering portal pressure are 
more effective and may be necessary in the majority of patients. However, as a result of local 
anatomy, in particular extensive thrombosis of the splanchnic venous system, concomitant 
diseases and the condition of the patient, this may not always be feasible.  
This was a long-term follow-up study of all consecutive patients presenting with bleeding 
ectopic varices in our hospital. This may have prevented potential biases associated with 
previous case series, in particular selective reporting of successfully managed patients or 
preliminary conclusions with respect to therapeutic results. Although we found that the 
efficacy of shunting procedures seems to be superior to local, non-shunt procedures, these 
observations should nevertheless be interpreted with caution since this was not a 
randomised controlled investigation to compare these treatment options. 
Our experience with colorectal and stomal variceal bleeding is in agreement with other 
reports (6-9) but more favourable results of local therapies have also been described (10-12). 
Local therapies may not always be safe since two of our patients with previous mild bleeding 
suffered a life-threatening haemorrhage following local injection therapy and required TIPS 
as an emergency procedure. Another case experienced massive bleeding after local suturing 
of rectal varices and underwent emergency shunt surgery. Even after shunting, varices may 
persist due to major portosystemic shunting via the inferior mesenteric vein, and obliteration 
of this afferent vein may be required (13). For stomal varices, removal of the stoma and 
restoration of the continuity of the bowel may be a simple solution; however frequently this is 
not a feasible option.  
In our experience the possibility of small-bowel, intraperitoneal and rectal variceal bleeding, 
in particular, is often not considered as a potential cause of gastrointestinal bleeding in 
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patients with portal hypertension, resulting in delays in diagnosis and proper management. 
Intraperitoneal variceal bleeding is associated with high mortality (1) and, once diagnosed, 
should result in the construction of a portosystemic shunt as soon as possible. Probably, 
small bowel variceal bleeding should be treated in the same way. As illustrated by two of our 
cases, relatively simple surgery with local resection of the involved segment and 
disconnection of intestinal-peritoneal adhesions and collaterals may also provide sustained 
control of bleeding when shunting procedures are not possible.  
This study confirms that rectal varices continue to be misclassified as haemorrhoids (5,10). 
Rectal blood loss in a patient with portal hypertension and ‘haemorrhoids’ should be 
considered to be of variceal origin until proven otherwise. Transrectal ultrasonography now 
seems to be the diagnostic method of choice in case of doubt regarding the nature of 
anorectal vascular abnormalities (14).  
Embolisation of feeding portal collaterals has been proposed as a potential important 
therapeutic modality for bleeding ectopic varices (12,15). Our experience with this approach 
is limited since embolisation was performed in only one case (13). Given the necessity of 
gaining access to the portal venous system, either by a transjugular or transhepatic 
approach, we feel that in most cases it may be wiser to choose a TIPS procedure since it 
basically addresses the underlying problem of portal hypertension (9).  
Propranolol was reported to be ineffective in six patients with stomal varices (16). We are not 
aware of other data regarding the use of pharmacological therapy for ectopic variceal. In the 
current series propranolol or other vasoactive drugs were not used. Obviously, there is ample 
room for further evaluation of the effects of pharmacological, as well as other, therapies. 
Considering the rarity of ectopic variceal bleeding, multicentre collaboration seems a 
prerequisite for conducting meaningful studies.   
In summary, when confronted with patients with portal hypertension and haemorrhage, which 
cannot be explained by gastro-oesophageal varices, the possibility of ectopic variceal 
bleeding should always be a main consideration. In our experience local therapeutic 
procedures frequently fail to provide long-term control of bleeding. Therefore, a 
portosystemic shunt procedure should probably be considered in all cases. If this is not 
possible a number of other therapies may occasionally be successful.  
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Table 1  Patient characteristics      
n=22 
 
age (years; mean, SD, range)    52.1 ± 15 (24-79) 
females/males      7/15 
aetiology of portal hypertension 
 portal vein thrombosis    3 
 cirrhosis: 
  - alcohol    7 
  - PBC     3 
- PSC     3 
- autoimmune hepatitis   1 
- hepatitis B    1 
- hepatitis C + portal vein thrombosis 1 
 nodular regenerative hyperplasia  1 
 myelofibrosis     1 
 idiopathic portal hypertension   1 
Child-Pugh class1 A/B/C    9/7/3 
previous gastro-oesophageal variceal bleeding  7 
location of ectopic varices 
 - rectum     8 
- stoma      4 
 - intraperitoneal     3 
 - duodenum     2 
- jejunum     1 
 - ileum      2 
 - skin      2 
  
transfusions2 (mean; SD, range)   10.8 ± 25 (0 - 118)            
 
1not determined for patients with portal vein thrombosis 
2 units of packed red cells administered during initial bleeding episode in our hospital 
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Figure 1   
Kaplan-Meier plot representing the proportion of patients without recurrent bleeding after local 
therapies (A; n=19) and second line therapy (B; n=11). 
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ABSTRACT 
 
Four patients with portal vein thrombosis, three men of 51, 45 and 31 years and one woman of 
22 years, presented with symptoms or signs of biliary obstruction. Laboratory investigations 
revealed cholestasis. Cholangiography demonstrated smooth indentations of the common bile 
duct consistent with external compression by collateral veins. The clinical course varied from 
spontaneous resolution of both symptoms and serum biochemical abnormalities to persistent 
cholestasis. In two cases, surgical treatment (splenorenal shunt and hepaticojejunostomy) 
failed due to the presence of numerous collateral veins. Biliary strictures secondary to the 
formation of a portal cavernoma, so-called portal biliopathy, is a fairly unknown complication of 
portal vein thrombosis. Although the majority of patients are asymptomatic, porto-systemic 
shunt surgery or endoscopic biliary intervention may be indicated in symptomatic cases. 
 
Introduction 
A network of collateral veins may develop in the hepatoduodenal ligament following thrombosis 
of the portal vein (1-3). Ultrasonographic imaging of this conglomerate of veins, which is called 
a portal cavernoma or cavernomatous transformation of the portal vein, may produce a 
characteristic picture (Fig 1). 
The most frequent complication of portal vein thrombosis is bleeding from oesophageal or 
gastric varices (1, 4) or, less common, from ectopic varices in the duodenum or rectum (5). A 
rare and relatively unknown complication of portal vein thrombosis, involving the biliary tract, 
will be discussed by means of the case histories described below. 
 
Case histories 
Patient A, a 51-year-old male, presented with oesophageal variceal bleeding 20 years ago. 
Treatment consisted of a splenectomy. Portosystemic shunt surgery failed due to massive per-
operative blood loss from collateral veins. On the basis of histological, ultrasonographical and 
angiographical examinations the diagnosis ‘thrombosis of the portal and superior mesenteric 
veins’ was made. A cause could not be identified. 
Ten years ago, he presented for the first time with abdominal pain, jaundice, dark urine and 
discoloured stools. Laboratory investigations revealed cholestasis (Table I). Endoscopic 
retrograde cholangiopancreatography (ERCP) demonstrated multiple strictures of the common 
bile duct. A diagnosis of primary sclerosing cholangitis was considered likely.  
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Figure 1. Ultrasonography of a portal cavernoma. 
 
Within two weeks symptoms disappeared and serum liver tests normalized. Two years later, 
the same signs and symptoms recurred. At ERCP small intrahepatic stones were found in 
addition to the previously known abnormalities. A nasobiliary drain (Fig 2) was introduced for 
lavage of the biliary tree. Treatment had to be stopped because of the development of fever 24 
hours later. The symptoms disappeared after antibiotic therapy and the patient was discharged 
in good general condition. After a duodenal variceal haemorrhage 1 year later and recurrent 
oesophageal variceal bleeding 2 years later, endoscopic sclerotherapy was initiated resulting in 
variceal eradication. One year ago he presented again with jaundice. ERCP revealed small 
concrements and smooth, undulating strictures of the common bile duct. Some small stones 
drained off after papillotomy. Just like six years ago the patient developed fever after biliary 
lavage but it disappeared as a result of antibiotic treatment. During the following year he was 
asymptomatic but serum liver tests indicating cholestasis persisted. Subsequently, an 
endoprosthesis was placed in the common bile duct for a period of 8 weeks. Six months later, 
he was asymptomatic and the serum liver tests had normalized. 
 
 
 
 
 
 
 
 
125 
Chapter 9 
 
Figure 2. Patient A; cholangiography using nasobiliary dain. 
 
Patient B, a 45-year-old male with a history of cholecystectomy for cholelithiasis and 
pancreatojejunostomy for chronic pancreatitis, was found by ultrasonography to have portal 
vein thrombosis with cavernomatous transformation. Because of recurrent pancreatitis two 
years later, an ERCP was performed; smooth, undulating strictures of the common bile duct, 
consistent with venous impressions, were demonstrated (Fig 3). One year later he complained 
of upper abdominal pain; laboratory examination showed cholestasis (Table I). ERCP 
demonstrated smooth narrowing of the distal common bile duct, consistent with external 
compression, and slight bile duct dilatation with small calibre changes in the proximal part. A 
stent was placed endoscopically. Because of cholangitis due to stent clogging the 
endoprothesis had to be replaced on four occasions during a period of 6 months. An attempt to 
create a surgical biliodigestive anastomosis failed because of the presence of multiple venous 
collaterals. Subsequently, two sessions of endoscopic balloon-dilatation of the distal common 
bile duct were performed but the serum liver tests did not improve. It is not clear whether this 
was caused primarily by compression of the distal common bile duct due to enlargement of the 
pancreatic head or biliary abnormalities secondary to the portal cavernoma. Perhaps a 
combination of the two factors is responsible. Recently, a metal ‘self-expandable’ 
endoprosthesis was placed in the distal common bile duct. 
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Figure 3. ERCP showing smooth, undulating strictures of the common bile duct. 
 
Patient C, a 22-year-old female, presented with biliary colic-like pain and vomiting. Her medical 
history had been remarkable; the following diagnoses had been established: ‘polyartritis 
nodosa’, ‘recurrent pericarditis’, ‘superior vena cava syndrome due to mediastinal 
lymphadenopathy’, ‘agenesis of the intrahepatic part of the inferior vena cava’ and ‘multiple 
oesophageal and gastric variceal haemorrhages due to thrombosis of the portal, splenic and 
superior mesenteric veins. In contrast to previous investigations, laboratory examination 
showed hyperbilirubinaemia (Table I). At ultrasonography multiple venous collaterals 
surrounding the common bile duct were seen. ERCP showed a smooth, flexible narrowing in 
the distal common bile duct, consistent with compression by collaterals. The signs and 
symptoms disappeared spontaneously and did not recur within the next four years. 
 
Patient D, a 31-year-old male, had always been healthy until he was admitted with abdominal 
pain, fever and an infiltrate in the right quadrant 9 years ago. Laboratory examination showed, 
in addition to an elevated erythrocyte sedimentation rate of 75 mm/hour and leucocytosis of 
24.9x109 /l, liver abnormalities indicative of cholestasis (table 1). Blood cultures were positive 
for streptococci. Ultrasonography showed portal vein thrombosis with a portal cavernoma. 
ERCP demonstrated biliary abnormalities comparable to those seen in patients A and B (Fig 2, 
3). Despite extensive investigations no explanation for this clinical picture was found. The 
patient recovered spontaneously and the serum liver tests normalized within a period of 6 
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months. Two years later he presented with symptoms of acute appendicitis. At laparotomy a 
retrocaecal inflamed appendix with adhesions to surrounding structures was found. 
Microscopical examination of the excised appendix showed appendicitis with perforation and 
peritonitis. The patient remained asymptomatic for the next 9 years. Retrospectively, it seems 
plausible that the first period of abdominal symptoms and septicaemia was probably also the 
result of appendicitis. The septicaemia may have caused thrombosis of the portal vein and, 
subsequently, the bile duct lesions. 
 
Table 1   
Serum liver tests in the 4 patients with portal biliopathy at the time of  diagnosis. 
 
 upper limit of normal patient 
  A B C D 
 
Total bilirubin 
 
17 μmol/l 
 
149 
 
90 
 
28 
 
10 
Alkaline phosphatase 117 U/l 413 2765 64 908 
-glutamyltranspeptidase 49 U/l 322 627 29 512 
Aspartate aminotranspherase 37 U/l 127 211 15 26 
Alanine aminotranspherase 41 U/l 253 197 10 75 
 
DISCUSSION 
 
Portal hypertension secondary to biliary liver diseases, such as primary biliary cirrhosis and 
primary sclerosing cholangitis, is a well-known, frequently occurring finding. In contrast, biliary 
abnormalities resulting from (formation of venous collaterals in) portal hypertension are rare 
and relatively unknown. The patients had portal vein thrombosis in all published cases. 
Bile duct lesions in portal vein thrombosis, also called ‘portal biliopathy’ (6), is rarely seen in the 
western world since the prevalence of portal vein thrombosis is low (1). In contrast, in Asian 
countries such as India, portal vein thrombosis is much more common and is one of the most 
important causes of portal hypertension (7). The reason for this considerable difference in 
prevalence is unknown. In more than 90% of cases in an Indian study, a cause could not be 
found (8). Cholangiographical studies show that biliary abnormalities are often present (80-
100%) in these patients (8-10). The vast majority of these patients remain asymptomatic. Mild 
to moderate elevations of serum bilirubin, alkaline phosphatase and transaminase levels are 
often found (9, 10). However, severe complications, such as cholestatic jaundice, cholangitis, 
abdominal pain (6, 11, 12) and secondary biliary cirrhosis (11), can occur and may even be the 
first manifestation of portal vein thrombosis (10, 11). As demonstrated by the course of disease 
in some of our cases, cholestasis may be transient. This could result from the passage of 
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biliary sludge or concrements that were caused by the biliary strictures. Other possible 
explanations could be that biliary compression decreases over time due to the development of 
new venous collaterals elsewhere or due to initial other problems, such as septicaemia as in 
patient D. 
Two, not mutually exclusive, explanations for the pathogenesis of this disorder have been 
suggested in literature. In portal vein thrombosis portoportal collaterals may develop around 
the occluded part of the vein; this phenomenon can be considered a natural adaptation and by-
pass mechanism aimed at the maintenance of portal perfusion of the liver and reduction of the 
venous pressure in the venous splanchnic compartment. Collaterals that surround the bile 
ducts may lead to bile duct compression (8, 13). The second hypothesis is that thrombosis also 
occurs in the efferent veins and afferent arteries of the biliary tree during thrombotic occlusion 
of the portal vein. This might lead to ischaemic damage to the biliary ducts with subsequent 
development of fibrosis and strictures (10, 11). 
Imaging studies may show involvement of the entire biliary tree, but the abnormalities are 
usually limited to the common and left hepatic bile ducts (8, 10). Smooth, undulating narrowing 
is seen in the most characteristic cases. Strictures, segmental dilatation, irregularities of the 
bile duct wall, pruning of intrahepatic bile ducts (8, 10) and concrements (6, 8, 11) sometimes 
in combination with calcification of the portal cavernoma (12) can also be found. The 
abnormalities may mimic the ones that can be found in primary sclerosing cholangitis or 
cholangiocarcinoma (10, 14). Therefore, the terms ‘pseudo-sclerosing cholangitis’ or pseudo-
cholangiocarcinoma’ (9) has been used to describe the abnormalities. The biliary lesions in 
portal biliopathy can be distinguished in particular from the abnormalities in primary sclerosing 
cholangitis by the smoother, undulating narrowing of the biliary lumen (8, 10). Sometimes it is 
possible to visualize the collaterals in the wall of the bile duct by means of ultrasonography (Fig 
4). 
Experience with the therapeutic possibilities for this disorder is limited. The construction of a 
surgical shunt, presumably the most rational approach, may result in complete disappearance 
of the biliary abnormalities (11, 15 -17). Technically, however, this is not always feasible. If 
other veins, in addition to the portal vein, are also occluded, shunt surgery may be impossible. 
Finally, biliary abnormalities can persist after the construction of a shunt. This could be an 
argument for the hypothesis that some patients have fixed (possibly ischaemic) strictures. In 
these cases, balloon-dilatation (10) or hepaticojejunostomy (6) may be indicated in second 
instance. Endoscopic placement of a stent (12-14, 18) or balloon-dilatation (11) may be 
successful, with or without additional extraction of biliary stones (15). One should be aware of 
the problems and dangers of a surgical approach. Surgical exploration of the hepatoduodenal 
ligament and identification of the bile ducts can be associated with significant blood loss due to 
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extensive vascularisation (12), sometimes with a fatal outcome (6). If biliary tract surgery is 
considered, this should preferably be performed after portal decompression (6). 
Portal biliopathy should be included in the differential diagnosis for patients with portal vein 
thrombosis and cholestasis. A non-intervention policy seems justified for asymptomatic 
patients. For symptomatic patients, surgical or endoscopical treatment may be chosen, 
depending on the extent of the thrombosis and the type of the biliary lesions. 
 
Figure 4. Intraluminal ultrasonography within the common bile duct showing venous collaterals adjacent 
to the bile duct wall. 
 
Table 2   
Most important causes of biliary strictures (19) 
 
Primary sclerosing cholangitis 
Ischaemia of bile ducts 
Previous biliary surgery 
‘graft-versus-host’ disease 
Rejection of liver transplant 
Infusion of cytotoxic medication in the hepatic artery 
Cholangiocarcinoma 
Choledocholithiasis 
AIDS-related cholangiopathy 
Sclerosing pancreato-cholangitis (20) 
Portal vein thrombosis 
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ABSTRACT 
 
Background: The efficacy of endoscopic sclerotherapy for bleeding oesophagogastric varices 
secondary to extrahepatic portal vein obstruction in adult Caucasian patients is   poorly 
documented.  
Objective: To assess the results of endoscopic sclerotherapy for all patients with this condition 
who have been treated and followed in our hospital since 1982.  
Design: Prospective cohort study.  
Results: Twenty-one consecutive patients were included and followed during a mean period of 
79 months (range 6 - 162 months). Active bleeding, encountered in five patients, was 
controlled by sclerotherapy in all cases. Two patients received a porto-systemic shunt after 
initial sclerotherapy. In all but one of the remaining 19 cases sclerotherapy resulted in 
eradication of the varices. The mean bleeding risk after initiation of sclerotherapy was 0.02 
bleed/month/patient, which was lower than the estimated 0.13 bleed/month/patient prior to 
sclerotherapy. The actuarial rate of rebleeding at 5 years due to all causes and due to 
oesophagogastric varices was 35% and 28%, respectively. Two patients died, both from a 
hematological (pre-)malignancy. Actuarial 5-year survival was 95%.  
Conclusions: The results of this study are in agreement with findings for pediatric and Asian 
patient populations and support sclerotherapy as the primary treatment modality for 
oesophagogastric variceal bleeding in adult Western patients with portal vein thrombosis. Life 
expectancy for patients with this condition is determined by the underlying cause of the portal 
venous obstruction. 
 
INTRODUCTION 
 
In Asian countries extrahepatic portal vein obstruction (EHPVO) is a frequent cause of 
oesophagogastric variceal bleeding, with a reported association of nearly 50% in India (1). In 
contrast, in Western countries EHPVO accounts for only 5-10% of variceal haemorrhages 
(2,3).  
The efficacy of endoscopic sclerotherapy for this condition, which has been assessed mainly 
for children and non-Caucasian populations (4-9), is poorly documented for other populations 
(10,11). In this study we evaluated our experience with endoscopic sclerotherapy as the 
primary therapeutic modality for Western adult patients with variceal bleeding and EHPVO. 
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PATIENTS AND METHODS 
 
In 1982 our hospital decided to use endoscopic sclerotherapy (ES) as the primary therapeutic 
modality for patients with oesophagogastric variceal haemorrhage secondary to EHPVO. In 
this study all 21 consecutive adults with this condition who were admitted between January 
1982 and August 1996 were reviewed. The main patient characteristics are presented in table 
1. EHPVO was demonstrated by means of angiography or ultrasound examination in all cases. 
Histology was normal for the twelve patients who underwent a liver biopsy. In the remaining 9 
patients clinical, biochemical and radiological examinations showed no evidence for cirrhosis. 
Serum bilirubin, albumin and prothrombin time, which were frequently found to be abnormal 
immediately following an episode of haemorrhage, were consistently normal in all cases during 
follow-up. Twelve patients had previously received some form of therapy for variceal bleeding 
(table 1) and in each case variceal bleeding recurred before ES was initiated in our centre. 
ES was performed with flexible endoscopes. Sedation was accomplished with an iv injection of 
0.075 mg midazolam/kg. Oesophageal and gastric varices were treated according to the same 
protocol. Ethanolamine or 2% etoxysclerol were used as sclerosing agents. Variceal bleeding 
not responsive to injections of sclerosing agents and marked persistent bleeding following 
injections were treated with additional local injections of thrombin (12). Injections were 
intentionally intravascular, each injected volume was a maximum of 1 ml and the total volume 
per session never exceeded 40 ml. The aim of injection sclerotherapy was  complete variceal 
eradication; it was performed at weekly intervals until variceal thrombosis seemed likely. 
Subsequently the intervals between sessions increased to 1, 3 and 6 months, respectively, 
followed by annual re-assessment. Any persistent or recurrent varices were then injected until 
they were eradicated. 
Data were obtained by review of patient charts and endoscopy files. Patient follow-up 
continued until August 1996 or death of the patient. Variceal bleeding (13) and rebleeding (14) 
were defined according to internationally accepted criteria. Kaplan-Meier curves were plotted to 
estimate the probability of survival and rebleeding (15). 
 
RESULTS 
 
The mean duration of follow-up was 79 months, range 6 - 162 months. No patients were lost to 
follow-up. 
 
Age at presentation 
Figure 1 illustrates the range of ages of the patients at presentation. Three patients had their 
first variceal haemorrhage before the age of 15; each of these patients had suffered at least 
135 
Chapter 10 
four bleeding episodes before initiatation of ES. Eleven patients (52%) were older than 45 
years at the time of their first variceal haemorrhage.  
 
Active variceal bleeding 
In 5 patients active variceal bleeding was observed during endoscopy. ES was successful in 
achieving haemostasis in all cases.  
 
Variceal eradication 
After the initial ES two patients received a surgical shunt. In one case the policy of ES as 
preferred standard treatment was not followed and a distal splenorenal shunt was constructed. 
The other patient had a nearly fatal bleeding episode following several injections in another 
hospital and approximately 2 weeks after one session at our centre. At endoscopy the actual 
bleeding site remained obscure, but no evidence was found for bleeding from sclerotherapy 
induced ulcers. This patient received a mesocaval shunt for ongoing bleeding. ES resulted in 
eradication of oesophagogastric varices in 18 of the remaining 19 cases (95%). Eradication 
was achieved after a median period of 8.4 months (range 0.5 - 24) and 6 injections (range 2 - 
9). Variceal eradication had not yet been accomplished in a patient who died 6 months after 
the initial treatment. 
 
Recurrence of varices after eradication. 
After eradication, variceal recurrence was observed in 9/18 patients, after a mean period of 
16.5 months (range 1 - 73.5 months). Additional ES resulted in renewed eradication in all 
cases.  
 
(Variceal) Rebleeding 
Recurrent bleeding was observed in nine cases. Eight patients suffered one renewed bleeding 
episode from oesophagogastric (n=5) or duodenal varices (n=1) and from ES-induced 
oesophageal ulceration (n=2). One patient suffered a total of four haemorrhages from 
apparently normal gastric mucosa on three occasions after ES seemed to have resulted in 
disappearance of gastric varices and from oesophageal ulceration. In this intriguing patient 
thrombosis of all major splanchnic veins and complete obstruction of the inferior and superior 
vena cava were found. 
Most episodes of rebleeding were observed early after the initiation of ES: five patients 
haemorrhaged again before eradication of varices was achieved and within 2 months of the 
first injection. Two patients experienced recurrent oesophageal variceal bleeding after 1 year. 
The actuarial 5-year rate of rebleeding due to all causes and due to oesophagogastric varices 
was 35% and 28%, respectively (figure 2).  
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Estimated variceal bleeding rate prior to and following ES  
For nine patients sufficient data were available to determine the moment of development of 
EHPVO. For these patients the bleeding rate prior to and following ES treatment was 
calculated. Prior to ES, 30 variceal bleeding episodes occurred during 1615 months; the 
calculated incidence was one variceal haemorrhage every 54 months or a mean incidence of 
0.13 bleeds/month/patient. In 843 months after the initiation of ES three bleeding episodes 
were observed; the calculated incidence was one variceal haemorrhage every 281 months or a 
mean incidence of 0.02 bleeds/month/patient. 
 
Survival 
The 5-year actuarial survival rate was 95% (figure 3). There were two deaths during the 14-
year study period: one due to post-splenectomy complications in a patient with chronic myeloid 
leukaemia 6 months after initial ES and one due to septicemia in a patient with polycythemia 
vera 5 years after initial ES. 
 
Complications of ES 
A total of 179 ES procedures led to complications in 5 cases (24%). Symptomatic oesophageal 
stenosis developed in two patients who successfully underwent endoscopic dilatation. Bleeding 
from oesophageal ulcers, caused by previous sclerotherapy, was observed in three patients. 
Asymptomatic oesophageal ulcers following ES were not regarded as complications. 
 
DISCUSSION 
 
The results of this study indicate that variceal bleeding in adult patients with portal vein 
thrombosis can be managed successfully with endoscopic sclerotherapy. Active bleeding was 
controlled in all cases and there was no mortality associated with variceal rebleeding or 
complications. The observed rate of variceal rebleeding at one year was 20 %, which is 
substantially lower than the 50 % reported for patients with cirrhosis (16). During long-term 
follow-up recurrent variceal bleeding was rare, indicating that in this condition prolonged 
variceal eradication is feasible and is associated with virtually complete protection against  
rebleeding. The ultimate prognosis was determined by the underlying cause of the portal vein 
obstruction; during a mean follow-up of 79 months no mortality related to portal hypertension or 
to non-malignant underlying disorders was observed.  
Some aspects of the present study warrant discussion. Although we carefully included all 
consecutive cases with EHPVO and variceal bleeding treated during a 14 year period, the 
number of patients is small. Furthermore, two of the 21 patients (10%) received a 
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portosystemic shunt after initial ES, and the subsequent course was favourable in both cases. 
Finally, our hospital is a tertiary referral centre and selection bias may have resulted in under- 
or over-representation of certain patient categories. 
Most previously published studies of ES for bleeding varices secondary to EHPVO involved 
pediatric patients (4-7). These studies uniformly demonstrated gratifying results and, on the 
basis of their experience, all authors advocated ES as the therapy-of-choice for this condition. 
Remarkably few studies of adult, and especially Western, patients have been performed. 
Thatcher et al. from Cleveland reported on their results with ES for eight (seven adult or 
teenaged) patients with EHPVO (10). During a mean follow-up period of 24 months they 
observed 3 patients with rebleeding. ES was associated with decreased transfusion 
requirements. Kahn et al. published their extensive, 15-year experience with ES in Cape Town 
where they treated 55 adult and teenaged patients with EHPVO (11). Eradication of 
oesophageal varices was achieved in 80% of cases. Eleven patients suffered a total of 18 
renewed haemorrhages before variceal eradication and six patients haemorrhaged again on 
seven occasions after variceal obliteration. Four patients died: one of complications after 
surgery to control variceal bleeding, one of a ruptured splenic vein and two of a cardiac cause 
not related to portal hypertension. Neither report contains information on the ethnic 
composition of the patient group, and the South African patients in particular may have differed 
from our group of West European white patients. In addition, our patients were considerably 
older - mean age 48 years - than those treated by Thatcher (mean: 22 years) and Kahn et al 
(mean: 30 years). It is noteworthy that half of our patients were over 45 years of age at the time 
of presentation, confirming that in Western countries variceal bleeding associated with EHPVO 
can be encountered in patients of any age (17). 
Controversy and uncertainty exist with regard to the optimum therapy for patients with EHPVO 
and variceal bleeding. Unfortunately, a preference for endoscopic or surgical therapy cannot be 
based on the results of randomized controlled investigations. Favourable results of surgical 
therapy, mainly for children and young adults, have been reported by several groups (18-20). 
Warren et al, who treated 25 adult patients surgically, i.e. selective distal splenorenal shunts in 
most cases (21), reported absence of surgical mortality and rebleeding in only 3 cases. In six 
cases shunt stenosis required dilatation after 3-6 months. These 25 patients came from a total 
group of 70 patients with EHPVO and a history of bleeding varices and therefore constituted a 
highly selected group. The outcome of surgical intervention for other patients, many of whom 
had undergone previous operations, was poor.  
Orozco et al. performed the Sugiura procedure (paraoesophagogastric devascularization, 
oesophageal transection, splenectomy, vagotomy and pyloroplasty) (22) on 27, mainly 
teenaged or adult, patients. Recurrent bleeding was observed in only two cases. However, 
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since there was one surgical mortality and serious post-operative complications occurred in 
eight patients, this procedure seems unattractive as therapy of first choice.  
Our data highlight the problems associated with shunt surgery for patients with portal venous 
obstruction: in nearly half of our cases the thrombotic occlusion also involved the splenic and 
superior mesenteric veins; in 3 patients previously created shunts were unsuccessful and at 
least one-third of cases were at high-risk for thrombosis (and hence for shunt occlusion). 
Currently, most available data seem to support ES as the primary therapy for variceal bleeding 
secondary to EHPVO in both pediatric and adult patients. It has now been demonstrated 
convincingly that variceal band ligation is superior to ES for patients with cirrhosis (23). It 
seems likely that this will also apply for patients with EHPVO. Surgical therapy can probably 
best be reserved for patients who do not respond favorably to endoscopic treatment or who 
cannot undergo endoscopic treatment for other reasons (2,3,24). 
In conclusion, endoscopic injection sclerotherapy is effective and safe for managing variceal 
bleeding in adult West European patients with EHPVO. In general, life expectancy for these 
patients is excellent and mortality seems mainly to be determined by the presence of 
underlying (pre-) malignant conditions. 
 
Figure 1 
Range of ages of the patients at initial ES in our hospital. 
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Figure 2  
Kaplan-Meier curve showing the percentage patients free of: 
   a: oesophagogastric variceal rebleeding  
   b: rebleeding from all causes. 
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Figure 3  
Kaplan-Meier curve showing the percentage patients dying from: 
   a: variceal bleeding 
   b: all causes. 
 
 
140 
Portal vein thrombosis and sclerotherapy 
Table 1  
Clinical features of patients with EHPVO 
Age: median; range (yr) 48; 16-74 
Sex (M/F) 7/14 
Variceal grade I/II/III/IV (no of patients)* 1/2/8/9 
Gastric varices (no of patients) 14 
Etiology of EHPVO (no of patients)  
 - protein S deficiency 2 
 - myelofibrosis 2 
 - polycythemia vera 1 
 - chronic myeloid leukaemia 1 
 - umbilical vein thrombosis 2 
 - resection of portal vein (pancreatic carc.) 1 
 - peritonitis/appendicitis 1 
 - cryptogenic 11 
Extent of venous obstruction (no of patients)*  
 - portal vein 8 
 - portal and superior mesenteric vein 3 
 - portal, superior mesenteric and splenic vein 8 
 - portal, splenic, superior and inferior mesenteric vein 1 
Previous treatment (no of patients)  
 - splenectomy 3 
 - surgical shunt 3 
 - propranolol 1 
 - endoscopic sclerotherapy (other clinic) 5 
 - conservative 6 
 
* not documented in one patient 
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SUMMARY AND DISCUSSION 
 
Chapter 1 provides a general introduction to this thesis. Relevant aspects of anatomy and 
pathophysiology of portal hypertension are reviewed, emphasizing the concepts of collateral 
and hyperdynamic circulation.  
 
Chapter 2 shows the results of a study evaluating the value of a barium swallow for 
diagnosing oesophageal varices. We found that this simple radiological method allows 
diagnosis of varices with acceptable reliability. Barium swallow could be used when 
endoscopy is ill tolerated or not acceptable to the patient. However, endoscopy is, and will 
remain, the standard diagnostic method. The disadvantage of more subjective interpretation 
is counterbalanced by providing additional information on the color and other variceal 
characteristics as well as on other lesions in the upper gi-tract, including the presence of 
gastric varices and portal hypertensive gastropathy.  
 
Chapter 3 suggests that the well-known NIEC system for assessing the risk for variceal 
bleeding can be further improved by a number of modifications. These results may of interest 
particularly from a scientific point of view. This study also confirms that variceal size, the 
presence of local variceal abnormalities (‘red spots’) and the degree of liver insufficiency 
have prognostic significance for the prediction of a first variceal bleeding episode.  
 
Chapter 4 reports the results of a multicenter randomized controlled trial evaluating 
endoscopic sclerotherapy for the primary prevention of variceal bleeding. The main findings 
were that sclerotherapy did not improve the risk of variceal bleeding or mortality. However, 
death directly attributable to variceal bleeding was significantly lower in patients receiving 
prophylaxis as compared to controls. Also given the results of comparable studies, we do not 
recommend prophylactic sclerotherapy. Variceal band ligation has a number of clear 
advantages over sclerotherapy and may be considered for primary prophylaxis, particularly in 
high-risk patients and those patients who do not tolerate or respond to propranolol, the 
currently recommended first-line prophylactic treatment.  
 
Chapter 5 describes our experience with the use of thrombin as an injecting agent for 
treating active variceal bleeding. This study confirmed clinical impression that thrombin is 
highly effective in arresting bleeding, while no evidence was found for adverse effects. 
Unfortunately, thrombin is no longer commercially available. Currently available data suggest 
that intravenous administration of recombinant factor VIIa may be a highly effective 
alternative for treating active variceal haemorrhage as well as bleeding of other origin. 
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Interestingly, recombinant factor VIIa results in the generation of high concentrations of 
thrombin at the site of bleeding. 
 
Chapter 6. In a small randomized controlled trial TIPS was compared with endoscopic 
variceal band ligation in patients with a first or second episode of variceal bleeding. As 
expected, the incidence of rebleeding was significantly lower after TIPS, but this was not 
associated with improved survival. TIPS increased the risk of encephalopathy and the costs 
of this treatment were estimated to be higher. These results are in agreement with the 
findings of most other studies and suggest that TIPS is not a first-line therapeutic modality in 
the secondary prophylaxis of variceal bleeding. TIPS, however, may have advantages in 
particular patients groups such as patients with gastric varices or with other complications of 
portal hypertension, and this possibility clearly should be addressed by additional studies.   
 
Chapter 7 reports the experience obtained with TIPS in the University Hospital Rotterdam in 
a cohort of 82 patients with variceal bleeding, refractory ascites and other complications of 
portal hypertension, followed for 3-9 years. The main finding was that with regular 
surveillance and re-interventions when indicated the definitive loss of shunt function was 
17% at 5 years. Non-alcoholic etiology and increasing platelet counts were predictive for 
developing shunt insufficiency. For patients with variceal bleeding the 1 and 4 year rate of 
recurrent variceal bleeding was 21% and 27%, respectively. Recurrent bleeding was caused 
by shunt dysfunction and persistent portal perfusion of collaterals. TIPS was found to be 
beneficial for a relative small percentage of patients with refractory ascites; mortality in this 
group was 43% at 6 months. The overall risk for developing encephalopathy was 52% at 3 
years. Chronic or severe intermittent encephalopathy was observed for 20% of the patients 
after 3 years; age and serum creatinine were independent risk factors. Overall survival was 
61% at 1 year and 42% at 5 years; age, serum albumin and creatinine were independent risk 
factors for mortality.  
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Chapter 8. Ectopic varices are defined as portal-systemic collaterals occurring anywhere 
outside the gastro-oesophageal junction. Bleeding from these varices is a rare complication 
of portal hypertension. In this chapter we report our experience with 22 patients over an 
eighteen-year period, the largest reported series. We found that in the majority of patients 
local therapies, e.g. sclerotherapy, surgical sutures or reinsertion of enterostomies, fail to 
provide long-term control of bleeding and that a portal-pressure lowering procedure, TIPS or 
a surgical shunt, seems more effective. Therefore, a shunt procedure should at least be 
considered early in the course of patients presenting with bleeding from varices at ectopic 
sites.  
 
Chapter 9 shows the results of another retrospective study with long-term follow-up 
evaluating the efficacy of endoscopic sclerotherapy for variceal bleeding in patients with 
portal vein thrombosis, a rather infrequent condition in the Western world. The results of this 
study are in agreement with findings for pediatric and Asian populations. The observed rate 
of rebleeding (28% at 5 years) and the fact that mortality from variceal bleeding was not 
observed, supports endoscopic therapy as the primary treatment option for variceal bleeding 
in this condition. This study confirms that life expectancy for patients with portal vein 
thrombosis is determined by the underlying cause.  
 
Chapter 10 is dealing with portal biliopathy, a characteristic biliary complication of portal vein 
thrombosis. We report our experience and discuss the pathophysiology and therapeutic 
options of this unfamiliar condition. The clinical course of patients with bile duct strictures due 
to compression by collaterals may vary from a asymptomatic state to development of 
obstructive jaundice, severe infectious complications and secondary biliary cirrhosis. In 
general, for symptomatic cases endoscopic treatment seems the therapy of choice, but 
portal-systemic shunt surgery may be required in a subgroup of patients.  
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SAMENVATTING EN DISCUSSIE 
 
Hoofdstuk 1 geeft een algemene inleiding tot dit proefschrift. Relevante aspecten van de 
anatomie en pathophysiologie van portale hypertensie worden kort behandeld, met een 
nadruk op de begrippen collaterale circulatie en hyperdynamische circulatie.  
 
Hoofdstuk 2 toont de resultaten van een studie naar de waarde van röntgenologisch barium 
contrastonderzoek bij de diagnostiek van oesophagusvarices. Wij vonden dat met deze 
simpele radiologische onderzoeksmethode varices met acceptabele betrouwbaarheid 
kunnen worden vastgesteld. Dit onderzoek kan gebruikt worden wanneer endoscopisch 
onderzoek slecht verdragen wordt of niet acceptabel is voor de patiënt. Wij menen evenwel 
dat endoscopische diagnostiek de standaard diagnostische methode is en ook zal blijven. 
Het nadeel hierbij van een meer subjectieve interpretatie wordt gecompenseerd door het feit 
dat endoscopie niet alleen aanvullende informatie verschaft over de kleur en andere 
karakteristieken van varices, maar ook over andere afwijkingen in de bovenste tractus 
digestivus, zoals maagvarices en congestieve gastropathie.  
 
Hoofdstuk 3 suggereert dat het bekende NIEC systeem voor het bepalen van het risico van 
het krijgen van een varicesbloeding door een aantal modificaties verbeterd kon worden. 
Deze bevindingen lijken vooral vanuit wetenschappelijk perspectief interessant. Deze studie 
bevestigde dat de grootte van de varices, de aanwezigheid van lokale wandafwijkingen (‘red 
spots’) van de varices en de mate van leverinsufficiëntie prognostische betekenis hebben ten 
aanzien van het optreden van een eerste varicesbloeding.  
 
Hoofdstuk 4 toont de resultaten van een multicentrische gerandomiseerde trial betreffende 
endoscopische sclerotherapie bij de primaire preventie van varicesbloedingen. De 
belangrijkste bevinding was dat sclerotherapie niet leidde tot een lagere incidentie van 
varicesbloedingen of sterfte. De mortaliteit direct samenhangend met varicesbloedingen 
bleek evenwel significant lager in de groep profylactisch behandelde patiënten. Mede gelet 
op de resultaten van soortgelijke studies kan sclerotherapie voor de profylaxe van 
varicesbloedingen niet worden aanbevolen. Varices bandligatie heeft een aantal voordelen 
ten opzichte van sclerotherapie en zou kunnen worden overwogen bij de primaire preventie 
van bloedingen, met name wanneer er sprake is van hoogrisico patiënten of wanneer 
behandeling met propranolol, de huidige profylactische standaard therapie, niet wordt 
verdragen of ineffectief blijkt.   
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Hoofdstuk 5 beschrijft onze ervaring met het gebruik van thrombine bij injectietherapie voor 
acute varicesbloedingen. Deze studie bevestigde de bestaande klinische impressie dat 
thrombine zeer effectief is bij het tot staan brengen van bloedingen,  terwijl geen 
aanwijzingen werden gevonden voor bijwerkingen. Helaas is thrombine niet langer 
commercieel verkrijgbaar. Thans beschikbare gegevens suggereren dat intraveneuze 
toediening van recombinant factor VIIa zeer effectief zou kunnen zijn bij de behandeling van 
actieve varicesbloedingen en bloedingen van andere origine. Het is interessant dat 
toediening van recombinant factor VIIa hoge concentraties thrombine genereert ter plaatse 
van bloedingen.   
 
Hoofdstuk 6. In een gerandomiseerde gecontroleerde trial werd behandeling met TIPS 
vergeleken met endoscopische bandligatie bij patiënten met een eerste of tweede 
varicesbloeding. Niet onverwacht bleek de incidentie van recidief bloedingen significant lager 
na TIPS behandeling, maar dit ging niet gepaard met een verbeterde overleving. TIPS 
verhoogde de kans op ontwikkeling van encephalopathie en de kosten van deze behandeling 
waren hoger. Deze resultaten zijn in overeenstemming met die van de meeste vergelijkbare 
studies en suggereren dat TIPS geen eerstelijns behandelingskeus is bij de secundaire 
preventie van varicesbloedingen. TIPS zou evenwel belangrijke voordelen kunnen hebben bij 
bepaalde patiëntengroepen zoals patiënten met maagvaricesbloedingen of andere 
complicaties van portale hypertensie, en deze mogelijkheid verdient nadrukkelijk nadere 
bestudering. 
 
Hoofdstuk 7 beschrijft de ervaring met TIPS in het Academisch Ziekenhuis Rotterdam bij 82 
patiënten met varicesbloedingen, refractaire ascites en andere complicaties van portale 
hypertensie, die gedurende 3-9 jaar vervolgd werden. De belangrijkste bevinding was dat 
met reguliere surveillance en re-interventies wanneer geïndiceerd het definitieve verlies van 
shunt functie 17% was na 5 jaar. Een niet alcoholische etiologie van de leverziekte en 
hogere trombocyten waarden bleken voorspellend t.a.v. het ontwikkelen van 
shuntinsufficiëntie. Voor patiënten met varicesbloedingen was de kans op recidief 
(varices)bloedingen na 1 jaar 21% en an 4 jaar 27%. Recidief bloedingen werden 
veroorzaakt door shunt dysfunctie en door persisterende doorbloeding van collateralen. Een 
relatief klein deel van de patiënten met refractaire ascites had baat bij behandeling met TIPS; 
de mortaliteit in deze groep was 43% na 6 maanden. De kans op het ontwikkelen van 
encefalopathie was 52% na 3 jaar. Chronische of intermitterend optredende ernstige 
encefalopathie werd waargenomen bij 20% van de patiënten na 3 jaar; leeftijd en het serum 
creatinine bleken onafhankelijke risicofactoren. De overleving voor de gehele groep was 61% 
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na 1 jaar en 42% na 5 jaar; leeftijd, serum albumine en serum creatinine waren 
onafhankelijke risicofactoren voor sterfte.  
 
Hoofdstuk 8. Ectopische varices kunnen gedefinieerd worden als porto-systemische 
collateralen voorkomend buiten het gastro-oesophageale overgangsgebied. Bloedingen uit 
deze varices zijn een zeldzaam voorkomende complicatie bij portale hypertensie. In dit 
hoofdstuk  worden onze ervaringen beschreven bij 22 patiënten die gedurende een periode 
van 18 jaar werden gezien, waarmee dit de grootste gerapporteerde serie is. Wij stelden vast 
dat lokale behandelingen als sclerotherapie, chirurgische doorstekingen of het verplaatsen 
van een enterostoma, vaak onvoldoende zijn om recidief bloedingen te voorkomen en een 
ingreep die de portale druk verlaagt, TIPS of een chirurgische shunt, effectiever is. Daarom 
moet een shunt procedure vroeg in het beloop bij alle patiënten die zich presenteren met een 
ectopische varicesbloeding tenminste worden overwogen.  
 
Hoofdstuk 9 toont de resultaten van een andere retrospectieve studie met lange follow-up 
duur naar de effectiviteit van endoscopische sclerotherapie voor varicesbloedingen bij 
patiënten met een vena portae thrombose, een relatief weinig voorkomende aandoening in 
de Westerse wereld. De resultaten van deze studie zijn in overeenstemming met die van 
studies bij paediatrische en Aziatische populaties. De waargenomen kans op recidiveren van 
de bloeding (28% na 5 jaar) en het feit dat sterfte ten gevolge van varicesbloedingen niet 
werd waargenomen, ondersteunen de positionering van endoscopische sclerotherapie als de 
eerste lijnsbehandeling voor varicesbloedingen bij deze aandoening. Deze studie bevestigt 
dat de levensverwachting van patiënten met vena portae thrombose bepaald wordt door de 
aard van de onderliggende aandoening.  
 
Hoofdstuk 10 betreft portale biliopathie, een karakteristieke biliaire complicatie bij vena 
portae thrombose. Wij beschrijven onze ervaring en bespreken de pathophysiologie en 
therapeutische opties bij deze weinig bekende aandoening. Het klinisch beloop bij patiënten 
met biliaire stricturen ten gevolge van compressie door collateralen kan variëren van geheel 
asymptomatisch tot het ontstaan van obstructie icterus, ernstige infectieuze complicaties en 
ontwikkeling van secundaire biliaire cirrose. In de meeste gevallen lijkt endoscopische 
behandeling de therapie van keus, bij een deel van de patiënten kan het aanleggen van een 
porto-systemische shunt noodzakelijk zijn. 
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danig op de proef moet zijn gesteld. Hij weet dat ik bij verschillende gelegenheden een 
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uitvallen. De vrijheid welke hij mij liet bij het uiteindelijk tot stand komen van deze dissertatie 
heb ik zeer op prijs gesteld. Ik ben hem ook uitermate erkentelijk voor de wijze waarop hij mij 
vormde tot leverarts. Beste, zeergewaardeerde Solko, altijd heb ik ernaar gestreefd om het 
specialisme Maag-Darm-Leverziekten breed uit te oefenen en dit kon alleen maar doordat 
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De tweede die ik hier wil noemen is Mark van Blankenstein. Het was een bijzonder voorrecht 
om onder zijn leiding geschoold te worden in onze zo fascinerende discipline. Zijn 
onnavolgbare humor maakte het werken vaak tot een nog groter plezier. Hij is 
ontegenzeggelijk een bepalende factor in mijn loopbaan geweest. Ik dank hem voor zijn 
grote belangstelling en ook daadwerkelijke inbreng bij verschillende studies zoals 
opgenomen is deze dissertatie.  
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Vele jaren mocht ik zeer tot mijn genoegen samenwerken met ‘de’ statisticus, Wim Hop. Zijn 
adviezen en opmerkingen waren zonder uitzondering goed. Ik hoop dat het er nog eens van 
komt om samen een mooi stuk te schrijven over het analyseren van tijdsafhankelijke 
factoren, en vooral over hoe dit niet te doen, een onderwerp dat voor ons al jarenlang een 
voortdurende bron van vreugde vormt.  
 
Han Laméris is een excellente radioloog met grote klinische belangstelling en de voor 
interventieradiologie noodzakelijke karaktereigenschap van grote volharding. Het was een 
voorrecht met hem samen te werken. Gelukkig drong hij er destijds op aan om TIPS in het 
therapeutisch pakket op te nemen. Ik dank hem zeer voor al zijn inspanningen en essentiële 
bijdragen aan verschillende publicaties.  
 
Ik dank Ernst Kuipers voor zijn enthousiasme en interesse in mijn werk en ben hem dank 
verschuldigd voor de manier waarop hij op galante wijze de laatste noodzakelijke duwtjes 
gaf. Ik hoop nog vele jaren met veel plezier tezamen met hem te mogen werken aan de 
verder op- en uitbouw van de afdeling en na dit proefschrift een aantal andere terreinen 
verder te mogen verkennen.  
 
Ik dank alle collega-artsen met wie ik het voorrecht heb om samen te werken, en voor de 
gelegenheid die zij mij boden om het werk af te ronden. In het bijzonder dank ik Jan Dees 
voor zijn bijdrage aan mijn (endoscopische) scholing en de altijd prettige momenten van 
overleg. Ik heb veel van hem geleerd en blijf jaloers op zijn technische vaardigheden. Zonder 
anderen tekort te willen doen dank ik Rob de Man, Hans Brouwer, Harry Janssen, Sjoerd de 
Rave en Peter Siersema voor hun interesse en voor de veelvuldige en vaak uitermate 
plezante momenten van samenwerking, overleg en samenzijn. Ik ben ervan overtuigd dat 
een goede werksfeer en ook informele contacten, al dan niet met een glaasje wijn, in 
belangrijke mate de uiteindelijke teamprestatie bepalen.   
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In de loop der jaren hebben vele collega’s uit andere centra in grote mate bijgedragen aan 
de studies zoals in dit proefschrift beschreven en ik ben hen buitengewoon erkentelijk voor 
hun grote volharding en langdurige inspanningen. Ik wil hier met name noemen: Marijke 
Rasch, Clemens Bolwerk, Piet Batenburg, Sjoerd van der Werf, Jan Nicolai, Joost 
Scherpenisse en Jan van Hattum.  
 
Carlo Merkel from Padua is an outstanding researcher in the field of portal hypertension. 
Above all he is a modest and charming person and I have always enjoyed our discussions on 
the numerous occasions we met. It was my great pleasure to participate in a study he 
initiated on prognostic risk factors for bleeding. I thank him and his Italian colleagues for 
allowing me to incorporate this study in my thesis.    
 
Een goede secretaresse is het halve werk en met name de volgende excellente dames 
hebben mij in de loop der jaren bijgestaan: Kim van der Haar, Annelies Schipper, Marcelle 
Houtman, Sylvia de Vlaming en Margriet Leeuwesteijn. Beste, lieve Margriet, zeer veel dank 
voor de vakkundige en snelle wijze waarop je me de laatste maanden steeds van dienst was. 
Annelies, zelfs vanuit het diepe Zuiden van Frankrijk gaf je vaak blijk van je voortdurende 
interesse. Ik dank jullie voor de uiterst plezierige wijze van samenwerken.   
 
Als relatief ouwe bok was het een waar genoegen om de laatste jaren intensief met jonger 
volk samen te werken. Beste Frank Wolfhagen, Bart van Hoogstraten, Frank Vleggaar en 
Pieter ter Borg, het was een groot voorrecht en genoegen jullie te leren kennen en tezamen 
op succesvolle wijze onderzoek te verrichten op het gebied van cholestatische leverziekten. 
Frank Vleggaar en Pieter ter Borg hebben zich daarnaast ook aan het onderwerp portale 
hypertensie bezondigd en ik dank hen voor hun essentiële inbreng bij een aantal studies en 
publicaties. Beste Pieter, zonder jou was hoofdstuk 7 een utopie gebleven. Vele arts-
leveronderzoekers, die mij allang zijn voorafgegaan met een proefschrift, mocht ik de 
afgelopen jaren leren kennen en ik vlei mij graag met de gedachte dat zij mij mentaal jong 
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hebben gehouden. Meerderen van hen hebben gemeend ook mdl-arts te willen worden en 
het is uitermate bevredigend om bij sommigen een rol in de opleiding te kunnen spelen.  
 
Bart van de Berg en Christien Groeninx van Zoelen hebben als intensivisten vaak een 
cruciale rol gespeeld bij de behandeling van patiënten met varicesbloedingen en ik dank hen 
voor de constructieve samenwerking, hopende dat er nog eens een dag moge aanbreken 
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Abel.  
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wil ik Coby van Vuuren, Geertje Kooyman en Anja Frankhuizen, net als ik behorend tot de 
generatie van oudere jongeren,  danken voor de bijzondere wijze waarop al zo lang lief en 
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Paul Wilson, Dr. A.Z. Ginai, Henry Snobl, Mirjam van Donselaar en verder al diegenen die ik 
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Tenslotte: Marlies, Thomas, lieve Ma, lieve schoonouders, Ard en Hans: jullie betekenis is 
moeilijk onder woorden te brengen. Anneke, liefste, tegen jou weet ik al helemaal niet wat 
hier te zeggen. Kus! 
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De auteur van dit proefschrift werd geboren op 19 oktober 1952 te Krimpen a/d IJssel. Na 
het behalen van het einddiploma HBS-B aan het Rotterdams Lyceum in 1971 studeerde hij 
Geneeskunde aan de Rijksuniversiteit Leiden en behaalde het artsdiploma in 1977. Tijdens 
het vervullen van de militaire dienstplicht was hij gedetacheerd in het Militair Hospitaal ‘Dr. A. 
Mathijssen’ te Utrecht en volgde aldaar het eerste jaar van de opleiding tot internist (opleider 
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Ziekenhuis te Leiderdorp (opleider: dr. W.J. van Amstel) en vanaf 1979 in het Bergweg 
Ziekenhuis te Rotterdam op de afdeling van dr. J. Silberbusch (opleider: dr. G.J.H. den 
Ottolander). In 1982 werd hij ingeschreven in het specialistenregister als internist. Vanaf 
1984 was hij als internist/onderzoeksarts en vanaf 1988 als staflid werkzaam in het 
Academisch Ziekenhuis Rotterdam, eerst op de afdeling Interne Geneeskunde II (hoofd prof. 
J.H.P. Wilson) en sinds 1998 tot heden op de afdeling Maag,- Darm-, en Leverziekten (hoofd 
ad interim prof. dr. S.W. Schalm, vanaf augustus 2000 hoofd prof. dr. E.J. Kuipers). Hij 
volgde de specialisatie tot maag-darm-leverarts onder M. van Blankenstein en werd in 1995 
ingeschreven in het desbetreffende register. Vanaf 1984 werden studies op het gebied van 
portale hypertensie verricht onder supervisie van en in nauwe samenwerking met prof. dr. 
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Cirrhose en Primaire Scleroserende Cholangitis. Hij is gehuwd met Anneke en heeft twee 
kinderen, Marlies en Thomas. 
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DIAGNOSTIC AND THERAPEUTIC GUIDELINES FOR BLEEDING FROM 
OESOPHAGEAL, GASTRIC AND ECTOPIC VARICES.
 
Chapter 12 
Pre-primary prophylaxis (prevention of development) of varices 
1. In patients with liver disease therapeutic efforts to prevent the development of 
portal hypertension and varices are essential. Prevention and adequate diagnosis 
and treatment of chronic liver disease are the cornerstones to accomplish these 
goals.  
2. Currently, no specific treatment has been identified. Pre-primary prophylaxis with 
propranolol was found to be ineffective (1).  
 
Diagnosis of varices in patients without known (large) varices 
1. Diagnosis of varices is relevant considering the potential of prophylactic 
treatment. 
2. In patients with chronic liver disease and normal platelet counts the presence of 
varices is unlikely (2).  
3. Patients with possible portal hypertension should undergo endoscopic 
examination. Patients with small varices should undergo repeat endoscopy after 
one year (3). Patients without varices should be reinvestigated at two-year 
intervals, but the frequency of repeat endoscopy should take into account the 
etiology, activity and severity of liver disease (4). 
4. Radiological examination can be used when endoscopy is not acceptable to the 
patient (5). 
5. There is no data available regarding the policy in patients with repeated negative 
examinations or stable findings.  
 
Prevention of first variceal bleeding 
1. In general, aspirin and non-steroidal anti-inflammatory drugs should preferably be 
avoided in patients with varices since these agents may cause variceal bleeding 
(6).  
2. There is no data whatsoever indicating that (blind) introduction of nasogastric 
tubes or the consumption of e.g. chicken or fish is risky in patients with varices.  
3. For patients with non-cirrhotic portal hypertension no data are available to support 
any specific prophylactic treatment.  
4. All patients with large varices should be treated (7, 8). Varices larger than grade II 
(scale I-IV) are considered large.  
5. The first line treatment is propranolol or nadolol. The dose should be increased to 
achieve a 25% reduction in resting heart rate or down to 55 b.p.m. or 
development of symptoms (4).  
6. Slow-release propranolol is recommended to improve compliance. 
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7. There is no consensus how to treat noncompliant patients or patients who have 
contraindications of intolerance to β-blockers. Available evidence does not 
support other pharmacological treatment (4). Prophylactic band ligation is a 
reasonable choice in this situation (9-11)   
 
Acute bleeding from oesophageal and gastric varices 
1. A diagnosis of oesophageal variceal bleeding can be made when active bleeding 
from varices or the ‘white nipple’ sign (fibrin plug) is observed. The diagnosis can 
also be established when endoscopy is performed within 24 hours of onset of 
haematemesis or melaena, or when blood is found in the stomach, and varices 
are present in the absence of other potential bleeding sources (12).  
2. Endoscopy should be performed as soon as possible after admission, especially 
in patients with clinically significant bleeding or in patients with features 
suggesting cirrhosis. In mild bleeds, causing neither haemodynamic changes nor 
requiring blood volume restitution, endoscopy can be done electively (13). 
3. Endotracheal intubation is mandatory if there is any concern about lung 
aspiration, particularly in patients undergoing endoscopy with ongoing or recent 
haematemesis, encephalopathy and circulatory instability (13).  
4. In suspected variceal bleeding vasoactive drugs should be started as soon as 
possible. Institution of this treatment should not be delayed until diagnostic 
endoscopy has been performed (13).  
5. Currently, there is no clear preference for terlipressin, somatostatin or octreotide. 
In patients confirmed to bleed from varices drug therapy can be maintained for up 
to 5 days (13).  
6. Antibiotic prophylaxis, e.g. oral norfloxacin 2 x 400 mg/day for 10 days, is an 
integral part of treatment and should be instituted from admission (13, 14). 
Initially, intravenous antibiotics may be preferred e.g. ciprofloxacin or a 
cephalosporin.   
7. Lactulose, e.g. 2 x 30 ml/day, should be given to prevent hepatic encephalopathy 
(13). 
8. In acute oesophageal bleeding either band ligation or injection therapy can be 
used (13). Band ligation is technically more difficult than injection therapy in cases 
with active bleeding. Injection of tissue adhesives is particularly effective for 
stopping active bleeding; injection volumes should not exceed 1 ml.   
9. There is no consensus on the treatment of gastric varices (8). Injection of tissue 
adhesives is now the endoscopic therapy of choice (15, 16). In patients with 
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extensive varices, inadequate endoscopic therapy or previous gastric variceal 
bleeding, TIPS should be sincerely considered as the therapy of choice (17, 18).  
10. In patients with gastric, especially large fundus, varices, the possibility of ‘left-
sided’ of ‘segmental’ portal hypertension should always be considered. In this rare 
condition splenectomy may be curative (19).  
11. Endoscopic therapy is the treatment of choice for oesophagogastric bleeding in 
patients with portal vein thrombosis (20). 
12. Balloon tamponade is an effective, temporary therapy for massive variceal 
bleeding (13).  
 
Prevention of recurrent bleeding 
1. Consensus is that either β-blockade (propranolol) or endoscopic band ligation is 
the first-line treatment to prevent recurrent variceal haemorrhage (21).  
2. Combinations of drug treatment and endoscopic treatment have not been found to 
be superior (21, 22).   
3. Band ligation is the preferred treatment for patients who have bled while on β-
blockers (21).  
4. There is no consensus on the definition of ‘failed’ therapy. In general, a second 
episode of recurrent variceal bleeding may be considered as reflecting failed 
therapy. For all patients with multiple episodes of variceal bleeding liver 
transplantation should be considered. The most appropriate therapy for patients 
failing on first-line therapy is TIPS, especially for patients with advanced (Child 
class B ore C) liver disease. For Child class A and non-cirrhotic patients a surgical 
shunt may also be considered (21).  
 
Ectopic variceal bleeding 
1. Ectopic variceal bleeding is rare. In patients with portal hypertension and 
unexplained (gastrointestinal) blood loss bleeding from ectopic varices should be 
considered (23, 24)  
2. Previous abdominal and pelvic surgery is a main risk factor for developing ectopic 
varices (23). 
3. Rectal bleeding in patients with portal hypertension is caused by varices, and not 
by haemorrhoids, until proven otherwise (23). 
4. Intra-abdominal bleeding may be caused by ruptured peritoneal varices (23); 
urgent porto-systemic shunting is the therapy of choice. 
5. Local therapies are likely to fail and a shunt procedure should be considered in 
patients with bleeding from ectopic varices.   
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